


CONSENSUS STATEMENT

Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited prior to publication. The authors are solely responsible for the content of the statements.

ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs

Cynthia R. L. Webster¹ | Sharon A. Center²  | John M. Cullen³ |
 Dominique G. Penninck¹ | Keith P. Richter⁴ | David C. Twedt⁵ | Penny J. Watson⁶

¹Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, Grafton, Massachusetts

²Department of Clinical Sciences, New York State College of Veterinary Medicine at Cornell University, Ithaca, New York

³Population Health and Pathobiology, North Carolina State Veterinary Medicine, Raleigh, North Carolina

⁴Ethos Veterinary Health and Veterinary Specialty Hospital of San Diego, San Diego, California

⁵Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado

⁶Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom

Correspondence

Cynthia R. L. Webster, DVM, DACVIM (SAIM), Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, 200 Westboro Rd., Grafton, MA 01536.
 Email: cynthia.leville-webster@tufts.edu

Abstract

This consensus statement on chronic hepatitis (CH) in dogs is based on the expert opinion of 7 specialists with extensive experience in diagnosing, treating, and conducting clinical research in hepatology in dogs. It was generated from expert opinion and information gathered from searching of PubMed for manuscripts on CH, the Veterinary Information Network for abstracts and conference proceeding from annual meetings of the American College of Veterinary Medicine and the European College of Veterinary Medicine, and selected manuscripts from the human literature on CH. The panel recognizes that the diagnosis and treatment of CH in the dog is a complex process that requires integration of clinical presentation with clinical pathology, diagnostic imaging, and hepatic biopsy. Essential to this process is an index of suspicion for CH, knowledge of how to best collect tissue samples, access to a pathologist with experience in assessing hepatic histopathology, knowledge of reasonable medical interventions, and a strategy for monitoring treatment response and complications.

KEYWORDS

ascites, bile acids, bilirubin, biopsy, coagulation, copper, hepatic, inflammation, liver, portosystemic shunting

Abbreviations: AAT, alpha-1 antitrypsin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APSS, acquired portosystemic shunts; aPTT, activated partial thromboplastin time; BT, Bedlington Terrier; CH, chronic hepatitis; CT, computed tomography; Cu, copper; CuCH, copper associated chronic hepatitis; DDAVP, desmopressin; D-Pen, D-penicillamine; FFP, fresh frozen plasma; GGT, gamma-glutamyl transferase; GSH, glutathione; H&E, hematoxylin and eosin; HE, hepatic encephalopathy; LDH, lobular dissecting hepatitis; LR, Labrador Retriever; MRI, magnetic resonance imaging; NRC, National Research Council; PH, portal hypertension; PT, prothrombin time; PVP, portal vein pressure; PVT, portal vein thrombosis; SAMe, s-adenosylmethionine; TEG, thromboelastography; TSBA, total serum bile acid.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. *Journal of Veterinary Internal Medicine* published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.




FIGURE 1 Primary and secondary chronic inflammatory hepatopathies in dogs. Inflammatory changes on a hepatic biopsy can be due to a primary or secondary hepatopathies. The primary hepatopathies represent a disease process centered on the liver and include chronic hepatitis which can progress to cirrhosis and lobular dissecting hepatitis. Primary hepatopathies are typically accompanied by evidence of hepatocyte necrosis/apoptosis as well as varying degrees of ductular proliferation and fibrosis. Secondary hepatopathies however occur due to a primary disease process elsewhere in the body, often involving the splanchnic circulation, that damage the liver. In this case inflammatory changes are limited to the portal areas and are not accompanied by fibrosis or hepatocyte necrosis/apoptosis. In this case the liver lesions do not represent the primary problem and one should search for the presence of an extrahepatic disorder. ALP, alkaline phosphatase; ALT, alanine aminotransferase; APSS, acquired portosystemic shunts; E, eosinophilic; L, lymphocytic; M, granulomatous; N, neutrophilic; P, plasmacytic; TSBS, total serum bile acids

1 | DEFINITION OF CHRONIC HEPATITIS

The panel accepts the World Small Animal Veterinary Association definition of chronic hepatitis (CH) as the most complete and accurate currently available^{1,2} (Figure 1, Supporting Information S1, Table 1). The key histologic features include the presence of lymphocytic, plasmacytic, or granulomatous inflammation (portal, multifocal, zonal, or panlobular) or some combination of these along with hepatocyte cell

death and variable severity of fibrosis and regeneration. Inflammation most commonly originates (or usually is more severe) in portal regions, often spilling over into the hepatic lobule (interface hepatitis). Cirrhosis reflects end-stage CH when substantial architectural distortion, fibrosis, and sinusoidal portal hypertension (PH) are present. A variant of CH called lobular dissecting hepatitis (LDH) is characterized by lobular inflammation accompanied by disruption of hepatic cords by fine fibrous septa, hepatocyte necrosis, and a marked ductular reaction (Figure 1, Supporting Information S1).

Because the liver is the recipient of the splanchnic venous outflow, it is exposed to inflammatory cytokines and endotoxin circulated from alimentary viscera. This may culminate in hepatic injury associated with modest inflammatory infiltrates in portal, lobular, or centrilobular regions without obvious hepatocyte death.^{3–5} This condition is best termed nonspecific reactive hepatopathy to systemic disease and is not consistent with CH as referred to in this document (Figure 1).

TABLE 1 Key points: Definition

- The panel accepts the World Small Animal Veterinary Association definition of chronic hepatitis (CH) as the most complete and accurate currently available.
- Care must be taken to differentiate CH from inflammatory/degenerative change because of extrahepatic disease in the splanchnic bed (nonspecific reactive hepatopathy to systemic disease).

2 | ETIOLOGY

Although there is evidence for infectious, metabolic, toxic, and immune causes of CH, most cases of CH in the dog are classified as idiopathic (Table 2).

2.1 | Infectious

To date there is no strong evidence of a viral etiology.^{76–81} Sporadic cases of CH have been associated with other infectious agents. Leptospirosis causes acute hepatitis and there is some evidence it can induce a chronic pyogranulomatous response.^{49–51} *Bacillus piliformis*, *Helicobacter canis*, and *Bartonella spp* have been identified in dogs with CH, but the evidence that these bacteria are the cause is not compelling.^{1,74,75,82} *Ehrlichia canis* has been associated with CH, and nonsuppurative hepatitis has been reported with babesiosis.^{54–58,83} Experimentally, anaplasmosis causes subacute hepatitis.^{58–60,75,84} *Leishmaniasis* is associated with CH, usually causing granulomatous inflammation.^{52,53} Multiple other systemic diseases can have hepatic involvement with the potential to cause CH (*Neospora*, toxoplasmosis, *Sarcocystis*, histoplasmosis, *Mycobacterium*, shistosomiasis, visceral larva migrans), but lesions typically are acute and necrotizing and part of a multisystemic disorder.^{61–73,85–88}

2.2 | Drugs and toxins

Several drugs and toxins have been implicated in causing liver injury.⁸⁹ Most often they cause acute injury, but in some instances CH or cirrhosis are potential sequela. Strong evidence indicates that treatment with phenobarbital, primidone, phenytoin, and lomustine can result in CH.^{90–96} In the case of phenobarbital, toxicity may be direct or related to altered metabolism of other xenobiotics. Several other drugs or toxins including carprofen, oxidbendazole, amiodarone, aflatoxin, and cycasin may lead to CH although they more commonly cause acute hepatic injury.^{89,97–106} In humans, it is estimated that herbal and dietary supplements are responsible for up to 18% of drug-induced liver injury (refer to <https://livertox.nih.gov/>).^{107–111} There are several anecdotal but poorly documented reports of liver injury in dogs given herbals or nutritional supplements. Clinicians should be vigilant in obtaining a complete drug history, including nontraditional therapies. Knowledge of commonly implicated agents and a high index of suspicion are essential for diagnosis.

The most common toxic injury causing CH in dogs is a consequence of hepatic copper (Cu) excess.^{6–46} Copper-associated CH (CuCH) may develop in any breed, including mixed breeds, but the Bedlington Terrier (BT), Dalmatian, Labrador Retriever (LR), Doberman Pinscher, and West Highland White Terrier are predisposed.

Abnormal hepatic Cu accumulation results from altered hepatic Cu excretion in bile, excessive dietary Cu intake or both. When Cu exceeds the hepatocyte transport and Cu-binding capacity, free Cu causes oxidative stress leading to hepatocellular degeneration and cell death with acute or chronic hepatic inflammation or both.^{112,113}

TABLE 2 Factors implicated in the etiology of chronic hepatitis (CH) in dogs and the consensus panel's opinion on the relative strength of evidence (strong, moderate, or weak) based on both the scientific literature and clinical experience

Etiology	Evidence	References
Immune	Moderate-strong	(see Table 5)
Toxic		
Copper	Strong	Many (6–46)
Metabolic		
Protoporphyrria	Moderate (but rare)	Kroeze (47)
alpha-1-anti-trypsin	Weak	Sevelius (48)
Infectious		
Leptospirosis	Moderate	Bishop (49) Adamus (50) McKallum (51)
Leishmaniasis	Moderate-strong	Gonzalez (52) Rallis (53)
Rickettsial	Weak	Egenvall (54) Mylonakis (55) Frank (56) Harrus (57) Nair (58) Hildebrandt (59) De Castro (60)
Mycobacteria	Moderate	Campora (61) Martinho (62) Naughton (63) Turinelli (64) Rocha (65)
Histoplasmosis	Moderate	Chapman (66) Bromel (67)
Protozoal (Neospora, Sarcocystis, Toxoplasma)	Moderate	Allison (68) Dubey (69) Fry (70) Hoon-Hanks (71) Magana (72) Dubey (73)
Bartonella	Weak	Gillespie (74) Saunders (75)
Viral	Negligible	Bexfield (76) Boomkins (77) Rakich (78) Van der Laan (79)

Strong evidence = numerous peer-reviewed scientific papers or case series.
Moderate evidence = a single peer-reviewed scientific paper or peer reviewed abstract.
Weak evidence = single case report, observational impressions, or extrapolation from human literature.

Altered Cu excretion primarily is associated with genetic mutations in proteins involved with hepatic Cu transport. In BT, autosomal recessive deletions in exon 2 of the ATP7B associated protein COMMD1 leads to CuCH.^{114–116} Copper concentrations can reach over 10 000 µg/g dry weight (dw) liver in this breed (normal hepatic Cu ranges from 120 to 400 µg/g dw).^{18,19,24,26,35,37} Genetic screening for COMMD1 deletion, along with selective breeding in BT, has

almost eliminated this disease. Recently, a candidate gene ABCA12 has been implicated independent of the COMMD1 deletion.¹¹⁷ Cu-mediated liver injury in LR may be influenced by mutations in ATP7B gene, which predispose to Cu accumulation, and mutations in ATP7A gene, the intestinal Cu transporter, which protects against Cu accumulation.¹³ Although genetic testing for these mutations is commercially available, the predictive and diagnostic utility of such testing currently is unknown.

Chronic cholestasis can cause hepatic Cu accumulation. Dogs, unlike humans and cats, are more resistant to Cu accumulation from cholestasis unless exposed to a high dietary Cu load.^{118,119}

The increasing frequency of CH cases beginning in the late 1990s correlates with the change in the premixes used to supplement Cu in commercial dog foods, which resulted in higher amounts of bioavailable Cu in diets.^{8,21,36,46,120,121} The panel believes that the National Research Council (NRC) and Association of American Feed Control Officials dietary guidelines, along with a change to more bioavailable Cu chelate premixes in commercial dog food, are linked with an increased prevalence of hepatic Cu accumulation in dogs (Table 3).^{122–130} The Cu concentrations in dog foods often exceed NRC recommendations by >2–4.^{8,120,128}

The diagnosis of CuCH encompasses several specific findings listed in Table 4. It is unknown what concentration of hepatic Cu is required to trigger CH in the dog. Historical studies have suggested that hepatic damage evidenced by increased serum alanine aminotransferase (ALT) activity, histopathologic morphologic changes or both begins when hepatic Cu concentrations exceed 1000 µg/g dw and almost invariably occurs when levels are >1500 µg/g dw.¹²⁹ However, considerable phenotypic variability exists with some dogs having “toxic” Cu concentrations (ie, >1000 µg/g dw) and no evidence of hepatic damage, whereas others with concentrations <1000 µg/g dw have substantial hepatic damage.^{21,32,34,35} The individual threshold for injury likely is influenced by environmental, physiologic, and genetic factors.^{131–134}

Table 4 lists the challenges associated with diagnosing CuCH. Determining whether hepatic Cu is the primary driving force for hepatic inflammation may require chelation and monitoring of surrogate indicators of hepatocyte recovery (normalization of serum enzyme activities, repeat liver Cu quantification, or both). Failed resolution of injury after appropriate chelation indicates another pathogenic mechanism. It is speculated that Cu injury can induce neo-epitope expression, inciting a secondary self-perpetuating immune response.

Rarely individuals with high concentrations of hepatic Cu can undergo an acute necroinflammatory crisis releasing Cu and causing a Coombs' negative hemolytic anemia.^{18,37,40} Additionally, an acquired Fanconi-like syndrome characterized by euglycemic glucosuria associated with renal Cu accumulation also can occur in some cases.^{135–138}

2.3 | Metabolic conditions

Alpha-1 antitrypsin (AAT) deficiency, caused by abnormal hepatic processing of AAT, results in hepatocyte retention of abnormally folded proteins causing CH.¹³⁹ Abnormal hepatic AAT accumulation is reported

TABLE 3 Dietary copper minimum allowances and copper content of dog foods

	NRC ^a minimum	AAFCO ^b minimum	Average dog food	Hepatic diets ^c
Copper concentration (mg/kg DM/d)	6 ^d	7.3 ^e	~15–25	~4.9

Abbreviations: AAFCO, Association of American Food Control Officials; DM, dry matter; NRC, National Research Council.

^aThe NRC recommendations were extrapolated for adult dogs based on observations of puppies fed diets containing 0.11–0.19 mg/100 kcal metabolizable energy/day that resulted in reduced serum ceruloplasmin concentrations. Serum ceruloplasmin concentrations however do not reflect copper (Cu) bioavailability and this assumption may be not valid for dietary Cu adequacy and dietary recommendations.^{35,122–125}

^bThe AAFCO recommendations for adult maintenance require a minimum of 7.3 mg/kg/DM/d with no maximum limit, regardless of the Cu source.¹ This recommended amount of Cu is typically added as a premix but fails to also include the Cu present in the base diet. Changes in premix formulations containing Cu oxide with a bioavailability of ~5% to that of Cu chelates (acetate, sulfate, and carbonate) with ~60%–100% bioavailability significantly increases the amount of Cu absorbed.^{126,127} Consequently, there is a large variation in the Cu concentrations in dog foods and many commercial foods have Cu concentrations that far exceed the NRC recommendations by 2–4 times or even more.^{8,120,128}

^cHepatic diets specifically Royal Canin Hepatic, Hills L/d and Purina HP Hepatic (Europe only) contain Cu concentrations below AAFCO and NRC requirements. These diets approximate the dietary Cu concentration of approximately 5 mg/kg DM that is the concentration that maintained affected Bedlington Terrier in a neutral Cu balance.

^dEquates to ~0.15 mg/100 kcal/d.

^eEquates to ~0.21 mg/100 kcal/d.

TABLE 4 Key points: Copper Associated Hepatitis (CuCH)

Diagnostic criteria of CuCH
1. Histological evidence of chronic hepatitis (CH) associated with hepatic copper accumulation most often located in centrilobular areas (Zone 3).
2. Histochemical copper staining showing hepatocyte copper accumulation in the centrilobular areas.
3. Hepatic copper quantitation with concentrations usually greater than 1000 µg/g dw liver. ^a
Challenges in diagnosis of CuCH
1. Lobe to lobe variability in copper concentration even in the absence of architectural changes.
2. Regenerative nodules have decreased copper accumulation.
3. Presence of significant fibrotic tissue decreases quantitative copper concentration.
4. Later stage inflammatory/fibrotic changes and pathologist inexperience complicate determination of lobular distribution.
5. Interpretation of the significance of marked copper accumulation which is not centrilobular.
6. A “gray zone” of quantitative hepatic copper concentrations between 600 and 1000 µg/g dw liver. ^b

^aSome dogs can have CuCH with lower hepatic copper concentrations.

^bCopper concentration at which CuCH exists is difficult to empirically state, and other factors such as pattern of copper distribution on biopsy and associated histopathologic damage, copper levels in diet, and clinical picture must be considered.

TABLE 5 Evidence for immune-mediated chronic hepatitis in the dog

Finding	Reference	Breed(s)
A lymphocytic infiltrate of the target organ	Defines CH (1)	
	Boisclair et al (2001) ¹⁴⁶	
	Sakai et al (2006) ¹⁴⁷	
Association with a MHC class II haplotype	Bexfield et al (2012) ¹⁴⁸	ESS
	Speeti et al (2003) ¹⁴⁹	DP
	Dyggve et al (2011) ¹⁵⁰	DP
Positive autoantibodies	Weiss et al (1995) ¹⁵¹	V
	Andersson and Sevelius (1992) ¹⁵²	V
	Dyggve et al (2017) ¹⁵³	DP
	Dyggve et al (2017) ¹⁵⁴	DP
Positive family history of disease	Speeti et al (1998) ¹⁵⁵	DP
	Johnson et al (1982) ²⁰	DP
	Dyggve et al (2011) ¹⁵⁰	DP
	Hoffman et al (2006, 2008) ^{9,14}	LR
	Fieten et al (2016) ¹³	LR
	Thornburg et al (1986, 1996) ^{32,34}	WW
Female predisposition	Andersson and Sevelius (1995) ¹⁵⁶	V
	Fuentealba et al (1997) ¹⁵⁷	V
	Johnson et al (1982) ²⁰	DP
	Crawford et al (1985) ⁷	DP
	Bexfield et al (2011, 2012) ^{158,159}	V, ESS
	Hirose et al (2014) ¹⁶⁰	V ESS
	Hoffman et al (2006) ¹⁵	LR
	Smedley et al (2009) ³⁰	LR
	Mandigers et al (2004) ⁴⁵	DP
	Dyggve et al (2011) ¹⁵⁰	DP
	van den Ingh et al (1988) ¹⁶¹	DP
A favorable response to immunosuppression	Strombeck et al (1988) ¹⁶²	V
	Favier et al (2013) ¹⁶³	V
	Sakai et al (2006) ¹⁴⁷	ECS
	Bayton et al (2017) ¹⁶⁴	ESS
	Kanemoto et al (2013) ¹⁶⁵	ACS
	Ullah et al (2017) ¹⁶⁶	V
Association with another autoimmune disease	Poitout et al (1997) ¹⁶⁷	V
	Shih et al (2007) ¹⁶⁸	LR

Abbreviation: ACS, American Cocker Spaniel; DP, Doberman Pinscher; ESS, English Springer Spaniel; LR, Labrador Retriever; MHC, major histocompatibility complex; V, various breeds; WW, West Highland White Terrier.

in American and English Cocker Spaniels with CH in the absence of circulating AAT deficiency.⁴⁸ Whether accumulation of hepatic AAT causes liver disease or merely reflects liver injury needs further

investigation. A rare metabolic disorder of porphyrin metabolism, erythropoietic protoporphyria, results in abnormal accumulation of porphyrins within hepatocytes and was reported as a cause of CH in a colony of German Shepherds.⁴⁷

2.4 | Immune-mediated CH

In humans, the diagnosis of autoimmune hepatitis relies on complex algorithms that make use of serum markers (enzymology, IgG, and autoantibodies including antinuclear antibodies, anti-mitochondrial antibodies, and anti-liver and kidney microsomal antibodies), and demonstrated absence of viral markers, excessive alcohol intake, or toxic drug or supplement administration, along with typical hepatic histology and response to immunosuppressive treatment.^{140–145} Immune-mediated hepatitis in humans is thought to occur in genetically predisposed individuals when exposure to certain triggers, such as a pathogen, drug, vaccination, toxin, or change in intestinal microbiome provokes a T-cell mediated immune response targeting liver-specific epitopes. The inciting trigger may not be apparent at the time of diagnosis.

Specific criteria for the diagnosis of immune-mediated hepatitis in dogs have not been developed. An immune basis in some dogs with idiopathic CH is suggested by several criteria (Table 5) which include the presence of lymphocytic infiltrates in the liver, abnormal expression of major histocompatibility complex class II proteins, positive serum autoantibodies, familial history of liver disease, association with other immune-mediated disorders, female predisposition, and favorable response to immunosuppression.^{1,7,9,14,15,20,32,34,146–163,165,167,168} A presumptive clinical diagnosis of immune-mediated CH in the dog requires elimination of other etiologies and a favorable response to immunosuppressive treatment. Currently, the lack of commercially available tests to detect liver-specific antibody-antigen interactions or cell immunosensitization in dogs with CH limits the definitive determination of an immune-mediated etiology.

Key points related to etiology are summarized in Table 6.

TABLE 6 Key points: Etiology

- Infectious etiologies are an uncommon cause of chronic hepatitis (CH), however a search for an infectious agent should be undertaken in cases having pertinent clinical findings or when there is pyogranulomatous hepatitis.
- The genetic test for COMMD1 in Bedlington Terrier is of value, but there is yet not enough information to make specific recommendations on the use of genetic tests in Labrador Retriever. A definitive diagnosis of CuCH in all breeds requires a liver biopsy and copper (Cu) quantitation.
- Excessive dietary Cu intake strongly influences hepatic Cu accumulation in both predisposed and non-predisposed breeds.
- Every liver biopsy should be evaluated for abnormal hepatic Cu as this is a common cause of liver injury and is treatable.
- Immune-mediated CH is presumed to occur in dogs, however a careful search for a primary underlying etiology should be undertaken before instituting immunosuppressive therapy for suspected immune-mediated CH.

3 | SIGNALMENT AND CLINICAL SIGNS

3.1 | Signalment

Details and evidence for breed, sex, and age predispositions are summarized in Supporting Information Table S1. There is strong evidence in ≥ 2 studies for an increased prevalence of CH in BT,^{24,35} Doberman Pinschers,^{7,20,43–45,150,153–156,158,162,169–173} LR,^{8,10,14,21,27,138,158,162,163,168,169,172} Dalmatians,^{39–41,157,158,169,174} American and English Cocker Spaniels,^{27,48,156,157,162,163,165,169,175} English Springer Spaniels,^{158,159,170,175,176} and West Highland White Terriers^{31,32,34,156,157,169} in several countries. In addition, in Sweden the Scottish Terrier, and in the United Kingdom the Cairn Terrier, Great Dane, Samoyed, Yorkshire Terrier, and Jack Russell Terrier are predisposed.^{156,158} There is some suspicion for a breed predisposition in Standard Poodles and American Cocker Spaniels, which appear to be overrepresented in reports on LDH.^{165,177–181}

The overall mean age when clinical signs are reported is 7.2 years (11 studies, $n = 983$ dogs). Disease duration before diagnosis is unclear.^{27,147,157–163,169,172,175} Reported age ranges in specific breeds are shown in Supporting Information Table S1. Dalmatians, Doberman Pinschers, and English Springer Spaniels present significantly younger than LR, English Cocker Spaniels, and Cairn Terriers with CH.¹⁵⁸ American Cocker Spaniels are significantly younger than English Cocker Spaniels with CH.¹⁵⁸ The age of presentation for CuCH and idiopathic CH do not appear to be different. Dogs with LDH present younger than do dogs with CH, with an average age of 2 years (3 months to 7 years, 4 studies with $n = 41$ dogs).^{27,177–180}

Reported sex ratios in individual breeds are shown in Supporting Information Table S1. Female predisposition occurs in LR, Dobermans, Dalmatians, and English Springer Spaniels.^{6,7,15,20,39,158,159,170} Male predisposition occurs in American and English Cocker Spaniels.^{156,165,182}

3.2 | Clinical signs

Clinical signs reported for dogs with CH are summarized in Table 7. Clinical signs typically are nonspecific, such as loss of appetite and lethargy.^{15,20,27,39,157,159,163,165,175,179,183–186} Less common but more specific signs of jaundice and ascites occur in approximately 33% of dogs and hepatic encephalopathy (HE) and bleeding tendencies occur in 6%–7%. Dogs with late stage CH or cirrhosis are more likely to have ascites and gastrointestinal bleeding.^{156,161,180,183,185,186}

A high incidence of ascites, icterus, and abdominal pain occurs in English Springer Spaniels.¹⁵⁹ American Cocker Spaniels also have a high incidence of ascites and acquired portosystemic shunts (APSS) in the absence of hyperbilirubinemia at the time of presentation.^{165,180} Over 80% of dogs with LDH present with ascites.^{27,165,177,179,180} Cases of granulomatous CH more commonly have fever and abdominal pain.^{25,66,187}

Chronic hepatitis seemingly has a long subclinical phase consistent with the observation that up to 20% of dogs with CH have increased serum liver enzyme activities in the absence of clinical illness.^{6,7,12,15,27,32,157,168,175}

TABLE 7 Clinical signs in dogs with chronic hepatitis

Clinical sign	Number of dogs ^{a,b}	Percentage of dogs
Decreased appetite	180	61
Lethargy/depression	165	56
Icterus	100	34
Ascites	95	32
PU/PD	91	30
Vomiting	71	24
Diarrhea	58	20
Hepatic encephalopathy	21	7.1
Melena	18	6.1
Abdominal pain	9	3.1
Gingival bleeding	2	0.6
Hematochezia	1	0.3
Hemoperitoneum	1	0.3

Abbreviations: PD, polydipsia; PU, polyuria.

^a $n = 15$ studies, 294 dogs.

^bReferences: 15,20,27,157,159,162,165,168,170,175,179,183–186.

Key points associated with signalment and clinical signs are summarized in Table 8.

4 | CLINICAL PATHOLOGY

4.1 | Serum enzymology

Details on serum liver enzyme activities from 27 retrospective studies of 848 dogs show increased serum ALT activity as the earliest indicator of CH (Table 9).^{7,12,15,20,25,32,39,156,157,159,163,168,170,175–180,183,184,186,188–194} Serum ALT activity thus is the best screening test for CH. However, histopathologic evidence of CH can exist in the absence of increased serum liver enzyme activity.^{192,193,195,196} Increased serum alkaline phosphatase (ALP) activity occurs later in CH. If both ALT and ALP activities are increased, the magnitude of ALT increase often exceeds that of ALP.^{15,163,165,168} As CH progresses and hepatic parenchyma decreases, ALP and gamma-glutamyl transpeptidase (GGT) activities increase compared to ALT (Table 6). Through the course of disease, considerable variation in serum ALT activity can occur suggesting that the extent of necroinflammation fluctuates over time.¹⁵⁵ In late stage cirrhosis, transaminases may decrease with parenchymal loss (Table 10).^{185,186,189,191,197} Although serum ALT activity has no prognostic application, it has some association with the severity of histologic injury. Less information is available regarding serum aspartate aminotransferase and GGT activities in CH, but they tend to mirror serum ALT and ALP activities,

TABLE 8 Key points: Signalment and Clinical Signs

- Canine chronic hepatitis (CH) can occur in any breed or cross breed, but breed, age, and sex predispositions are considered risk factors in some dogs with CH.
- The clinical signs of early CH are vague and nonspecific. When overt signs develop, they often represent complications of later stage disease.

respectively, although both are less sensitive. Evidence suggests that serum concentrations of some microRNAs, particularly miR-122, are increased with minimal liver injury in the dog in the absence of increases in ALT activity, and thus may have superior sensitivity over standard serum liver enzymology in detecting early CH.^{192–196}

4.2 | Function tests

Hyperbilirubinemia is reported in approximately 50% of dogs with CH and is a negative prognostic indicator (Table 9).¹⁷⁵ Because of the liver's large synthetic reserve for albumin synthesis, hypoalbuminemia is a late marker of hepatic synthetic failure. Hypoalbuminemia occurs in most dogs with LDH.^{177–180} Decreased concentrations of blood urea nitrogen and cholesterol develop in approximately 40% of dogs with CH, occurring most commonly in those with cirrhosis.¹⁶⁵ Hypoglycemia is rare in CH and more often is associated with acute liver failure.

Total serum bile acid (TSBA) concentrations are the most sensitive hepatic function test for CH.^{197–199} However, their sensitivity, particularly for early stage disease, is inadequate, which makes them poor screening tests for CH and thus should not be used as the basis for deciding to pursue hepatic biopsy.^{189,192,200} However, TSBA concentrations are uniformly increased when portosystemic shunting is present, thus their sensitivity for detecting cirrhosis and the presence of APSS is high.¹⁸⁹ Dogs with cholestasis (ie, hyperbilirubinemia) associated with hepatic disease will always have increased TSBA.

Hyperammonemia has similar sensitivity to detecting CH or cirrhosis and APSS as do TSBA, and it is somewhat more specific because it is not affected by cholestasis.²⁰⁰ However, it is much more technically difficult to accurately measure blood ammonia concentrations.^{197,201–204} Although hyperammonemia infers the presence of HE, HE can develop in the absence of high blood ammonia concentrations.^{204,205} Ammonium biurate crystalluria in dogs with CH provides evidence of episodic hyperammonemia.

TABLE 9 Common biochemical changes in dogs with chronic hepatitis

Parameter	Percent increased	Number of studies (# dogs) ^a
Inc ALT	85 ± 16	10 (250)
Inc ALP	84 ± 19	10 (250)
Inc AST	78 ± 10	3 (56)
Inc GGT	61 ± 12	5 (121)
Inc TSBA	75 ± 14	9 (109)
Dec BUN	40 ± 29	5 (65)
Dec albumin	49 ± 19	15 (323)
Dec cholesterol	40 ± 12	4 (118)

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; GGT, gamma-glutamyl transferase; TSBA, total serum bile acid.

^aReferences: 7,10,15,20,27,32,39,157,159,163,165,168,170,175,183–186, 188,189.

TABLE 10 Comparison of serum ALT and ALP increases in dogs with chronic hepatitis and/or cirrhosis

Disease	ALT fold increase	ALP fold increase	Number of studies (# dogs)
CH/cirrhosis ^a	7.5 ± 3.2	5.5 ± 2.5	24 (478)
Cirrhosis ^b	2.5 ± 0.3	4.8 ± 2.2	3 (61)

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; CH, chronic hepatitis.

^aReferences: 7,10,15,20,27,32,39,157,159,163,165,168,170,175,183–186, 188,189,191,192.

^bReferences: 170,185,188.

4.3 | Hematology and coagulation testing

Hematology and coagulation testing are discussed in Biopsy Acquisition and Interpretation sections.

4.4 | Urinalysis

Isothenuria is seen in dogs with polyuria and polydipsia. A transient acquired Fanconi-like syndrome characterized by euglycemic glucosuria may develop in dogs with CuCH and in other toxin-induced liver injuries when concurrent renal tubular injury occurs.^{34,39,49–51,135–138,159,168} The glucosuria in dogs with CuCH resolves with recovery from acute injury.

Key points associated with clinical pathology are summarized in Table 11.

5 | IMAGING

Abdominal radiographs estimate overall liver size, shape, and opacity, but are not sensitive to subtle variations.^{206,207} Microhepatitis is suspected when the gastric axis is displaced cranially and hepatomegaly when the liver extends beyond the costal arch with rounded edges. Radiographs are unreliable in assessing asymmetric change in hepatic size. Abdominal serosal detail is decreased when ascites is present.

Hepatic ultrasonography is the preferred imaging modality for the initial evaluation of dogs with suspected CH because it permits identification of alternative diagnoses or complicating factors (eg, PH, ascites, APSS, thrombi).^{207–209} Ultrasound imaging can assist in deciding on the most prudent method of tissue acquisition and may facilitate needle biopsy sampling.²⁰⁵ Hepatic ultrasonography provides information regarding size, shape, echogenicity, and echotexture of the parenchyma, as well as information on the biliary tract and main vessels.²⁰⁸ However, imaging the liver in dogs with CH can be challenging

TABLE 11 Key points: Clinical Pathology

- Persistent (>2 months) unexplained increases in serum alanine aminotransferase activity with or without other laboratory changes is the best screening test currently available for early detection of chronic hepatitis (CH).
- Abnormalities in hepatic function tests such as total serum bile acid (TSBA) and blood ammonia most often occur late in the course of CH in dogs.

because this organ is located mostly under the rib cage, and its conformation varies among breeds. This modality also is highly operator-dependent, and therefore the results of published work vary with the experience of the sonographer and the type of equipment used.

Ultrasound findings in the liver of dogs with CH or cirrhosis often are diffuse. Hepatic size remains subjectively assessed by estimating the position of the liver with the probe placed in a subcostal position. Generally, liver size is variable with CH, more often being small, especially with advanced disease.^{15,27,39,159,165,168,175,183,185} Several factors such as patient position and gastric distention may affect estimation of liver size. In late CH, when liver size is decreased, evaluation is more difficult.

The liver normally is hypoechoic compared to the spleen. The liver in CH tends to be hyperechoic because of the presence of fibrosis or glycogen-type vacuolation. As CH progresses, the echotexture of the liver becomes heterogeneous with small hypoechoic nodules. Heterogeneity may vary among liver lobes. Concurrent disease such as acute inflammation, glycogen or lipid vacuolar change, and benign nodular hyperplasia can affect liver size, contour, and echogenicity.

Mild or early grades of CH may affect liver size or echotexture minimally, which may account for the reported poor sensitivity of ultrasonography in detecting CH at different stages.^{209–213} Liver size was normal in 14%–57% of dogs with CH in several studies, but the stage of disease was unclear.^{6,15,27,168,183,185,211} Thus normal ultrasonographic appearance of the liver should not dissuade the clinician from hepatic biopsy in a dog with suspected CH.^{211,213}

The features of microhepatica, irregular hypoechoic nodules, and irregular margins often are seen in end-stage CH,^{170,185,186} although in some advanced cases the liver still can appear relatively normal. Ultrasonographic evidence of PH may accompany late-stage CH (Table 13). These signs include the presence of ascites, APSS, edema in the gallbladder wall, gastrointestinal wall or pancreatic region, decreased portal blood flow velocity (mean velocity < 10 cm/s), hepatofugal blood flow or both.^{215–219} Acquired portosystemic shunts usually appear as plexuses of tiny tortuous vessels located caudal to the kidneys, or as a splenorenal anastomosis flowing from the splenic vein to the plexus, the left renal vein, caudal vena cava, or aberrant vessels in the mesentery; all best seen with color or power Doppler.^{208,215,219} Determination of portal flow dynamics (velocity, direction of flow) is technically challenging and highly dependent on operator experience and skill.

Portal vein thrombosis (PVT) can develop as a complication of CH in dogs.^{220,221} In the presence of ascites, abdominal pain, and

thrombocytopenia, PVT should be suspected and the portal vein carefully evaluated for presence of a thrombus that can be nearly anechoic to moderately echogenic. Thrombi also may be discovered in other venous beds, most often involving splenic vasculature. Abdominal effusion, patient body conformation, or the presence of abdominal pain may obfuscate detection of PVT by ultrasound examination.²²²

The use of computed tomography (CT) and magnetic resonance imaging (MRI) to characterize liver architecture in CH has not been reported in dogs. However, CT angiography is of particular interest in dogs with small livers and those with suspected PH, PVT, or APSS.²¹⁹

In humans, MRI features can distinguish between acute versus chronic diffuse liver diseases by quantifying biomarkers such as lipid, iron, and collagen.²²³ Application of these techniques could change the diagnostic and therapeutic approach to chronic hepatopathies in the future.

Key points associated with imaging are summarized in Table 12.

6 | BIOPSY ACQUISITION

6.1 | Pre-biopsy considerations

The primary concern for any hepatic sampling technique is post-procedural hemorrhage. Although the risk of hemorrhage post-biopsy exists in dogs with CH, the prevalence is poorly documented. Published studies of post-biopsy hemorrhage including a heterogeneous group of hepatic disorders indicate a 1.2%–3.3% incidence of bleeding complications.^{224–229} However, many patients with moderate to severe coagulation abnormalities were pretreated with fresh frozen plasma (FFP) transfusions before liver biopsy likely influencing observed complications.

Assessment of bleeding risk in CH is challenging because of the liver's complex and antagonistic role in the synthesis and degradation of pro- and anti-thrombotic proteins and its role in fibrinolysis.^{214,230–233} Assessment by evaluation of prothrombin time (PT), activated partial thromboplastin time (aPTT), plasma fibrinogen concentration, platelet count, or buccal mucosal bleeding time (BMBT) does not consistently predict risk of bleeding after liver biopsy in humans.^{234–237} In humans, there is consensus that moderate to severe prolongations in PT and

TABLE 12 Key points: Imaging

- Abdominal ultrasound is the most useful and informative imaging modality for dogs with suspected chronic hepatitis (CH), but is highly operator dependent, its sensitivity is low, and no changes are pathognomonic or diagnostic for CH.
- Ultrasound helps to identify complications associated with CH such as acquired portosystemic shunts (APSS), ascites, splanchic thrombi, and gastrointestinal ulceration.
- Advanced imaging modalities such as CT angiography may be necessary to diagnose vascular anomalies like portal vein thrombi or APSS.

TABLE 13 Coagulation parameters in dogs with chronic hepatitis

Coagulation parameter	Percent changed	Number of studies (# dogs) ^a
PT prolongation	47 ± 30	10 (224)
aPTT prolongation	42 ± 15	10 (224)
Thrombocytopenia	23 ± 17	7 (117)
Anemia	34 ± 27	11 (237)
Hypofibrinogenemia	57 ± 32	7 (102)
Decreased protein C activity	69 ± 29	4 (61)
Decreased antithrombin	23 ± 17	2 (19)

Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time.

^aReferences: 7,15,27,157,159,165,183–186,214.

aPTT ($>1.5 \times$ upper limit of normal), platelet count $<50\,000/\mu\text{L}$, anemia (PCV $<30\%$), and low plasma fibrinogen concentration ($<100\text{ mg/dL}$) have some predictive ability in assessing bleeding risk and thus these variables have been incorporated into pre-procedural standard of care guidelines.^{237–240}

Coagulation and hematological abnormalities may exist in dogs with CH. Mild anemia develops in approximately one-third of affected dogs (Table 13) where it may reflect gastrointestinal bleeding from mucosal ulceration, coagulopathies, or anemia of chronic disease. Dogs with CH appear to be predisposed to duodenal ulceration.^{241,242} Microcytosis frequently accompanies APSS.¹⁸⁶ Mild subclinical thrombocytopenia occurs in approximately 23% of affected dogs, typically in later stage disease where it may be associated with a consumptive process or decreased production of thrombopoietin by hepatocytes.^{168,185} Thrombocytopathia may develop in some dogs with CH.^{243,244} Mild to moderate prolongations of PT and aPTT occur in approximately 40% of affected dogs presumably reflecting synthetic failure or vitamin K deficiency.²³⁰ The consensus panel recognizes inherent variability in point-of-care testing for PT and aPTT and that there is inconsistent concordance with reference laboratory testing. Low plasma concentrations of fibrinogen occur in 60% of affected dogs, particularly in those with late stage disease.^{161,165,183,231,244} Anticoagulants protein C and antithrombin are decreased in 70 and 23% of dogs with CH, respectively, and decreases may be more common in dogs with APSS.^{157,183,186,189,231,244}

Thromboelastography (TEG) commonly is used to evaluate coagulation status and guide clotting factor repletion and fibrinolytic treatments in human liver transplant patients. In humans, TEG analysis can predict bleeding tendencies in cirrhotic patients.^{245–247} Thromboelastography studies in dogs with CH suggest that hypocoagulable, hypercoagulable, or normocoagulable states exist,¹⁸³ with up to 25% of affected dogs being hyperfibrinolytic.¹⁸³ At this time, the value of TEG in predicting coagulation status in dogs with CH is unknown. Plasma fibrinogen concentrations seemingly reflect TEG indices of clot strength in dogs with liver disease.^{183,229,248,249} As such, plasma fibrinogen concentration is recommended for bleeding risk assessment in CH.^{250–252}

Despite the lack of studies in veterinary medicine that show correlation with in vitro coagulation studies and iatrogenic hemorrhage after liver biopsy, bleeding can be a serious complication of invasive procedures and there is value in identification of high-risk patients. The consensus panel's recommendations for coagulation assessment are summarized in Table 14. Preexisting anemia (PCV $<30\%$) decreases the threshold for development of hemodynamic instability after hemorrhage and may affect platelet dynamics, provoking hemorrhage.^{253,254}

If a liver biopsy is elective, and the patient is receiving drugs affecting coagulation, such drugs should be discontinued for an appropriate duration of time before biopsy.

In dogs identified with risk for bleeding or development of anemia, anticipatory preparation for potential blood component treatment is recommended. High-risk dogs ideally should have hepatic biopsy performed via laparoscopy where tissue injury is minor compared to

laparotomy and hemostasis can be more tightly controlled compared to ultrasound-guided needle biopsy methods. Strict attention to proper technique regardless of the method of biopsy is warranted, and dogs should be hospitalized overnight in a facility that can provide direct observation. There is not enough evidence to recommend routine prophylaxis with FFP or other blood products, vitamin K, or pro-tease inhibitors, and their use should be considered on a case-by-case basis. Although these interventions may have beneficial effects in correcting abnormal laboratory parameters in various clinical settings, there is little clinical evidence that they decrease the risk of bleeding in dogs with CH undergoing liver biopsy. Administration of cryoprecipitate and desmopressin (DDAVP) is warranted in dogs with proven von Willebrand disease.

Risks of hepatic biopsy other than hemorrhage include anesthetic complications, air embolism and pneumothorax (with laparoscopy), and infection.^{210,255}

6.2 | Sampling methods

The diagnosis of CH requires histopathologic evaluation of liver biopsy specimens. Hepatic sampling can be done by ultrasound-guided percutaneous core biopsy, at laparoscopy using a 5-mm cup forceps, or by wedge biopsy at laparotomy. The advantages and disadvantages of each method are highlighted in Supporting Information Table S2. Fine-needle aspirates have no role in the definitive diagnosis of CH, because they often miss inflammatory infiltrates, extent of fibrosis, or abnormal Cu accumulation.^{256–259}

In general, larger biopsy specimens obtained during laparoscopy or laparotomy are of better diagnostic quality, and are recommended for the diagnosis of CH. If biopsy specimens cannot be obtained by laparoscopy or laparotomy, 14–16 G percutaneous ultrasound-guided biopsies, if performed correctly, can provide adequate specimens.

During surgical procedures, biopsy specimens should not be obtained exclusively from the periphery of liver lobes if these appear fibrotic.²⁶⁰ Studies have shown that both central and peripheral biopsy specimens can be obtained safely.²⁶¹ Quantitative hepatic Cu measurement using 1 of the hepatic biopsy specimens is recommended. The specimen should

TABLE 14 Test used to determine risk of bleeding complications in dogs with chronic hepatitis

Bleeding risk assessment test	High risk
PCV	$<30\%$
Platelet count	$<50\,000/\mu\text{L}$
PT, aPTT	Either $>1.5 \times$ ULN
Fibrinogen	$<100\text{ mg/dL}$
vWF activity ^a	$<50\%$
BMBT ^a	>5 minutes

Abbreviations: aPTT, activated partial thromboplastin time; BMBT, buccal mucosal bleeding time; PT, prothrombin time; ULN, upper limit of normal; vWF, von Willebrand's factor.

^aIn predisposed breed such as Doberman Pinscher, Scottish Terrier, Shetland Sheepdog, Golden Retriever, Old English Sheepdog, Rottweiler, German Shepherd Dog, Schnauzer, Corgi, and Chesapeake Bay Retriever.

be taken from the least-affected region, avoiding regenerative nodules and highly fibrotic lobes, both of which may underrepresent hepatic Cu burden.^{262–264}

At least 12–15 portal triads are recommended for proper evaluation of hepatic biopsy specimens.²⁶⁵ This number of triads can be reliably achieved only if multiple needle ($n > 4$) or laparoscopic cup forceps biopsy specimens ($n = 2$ –4) are obtained.^{265,266} In 1 study, the diagnostic accuracy of 2 18-gauge needle biopsy specimens was compared to a gold standard of surgical wedge biopsy of the liver in 124 patients.²⁶⁷ The overall discordance between the 2 methods was 67% in dogs with CH with or without cirrhosis. Numerous studies have documented substantial variation among liver lobes in terms of gross appearance and histologic features in dogs with CH.^{226,267,268} This variation highlights the need to collect biopsy specimens from multiple liver lobes. These specimens are in addition to those needed for bacterial culture and Cu quantification.

Biopsy specimens should be handled carefully to avoid crush and fragmentation artifact. Tissue should be placed promptly into neutral buffered formalin. Inking of specimens allows identification of lobe origin when samples are embedded together for viewing on 1 slide. Additional biopsy specimens are placed immediately in appropriate transport media for aerobic and anaerobic bacterial culture and in an empty glass tube for Cu quantification.

Approximately 20–40 mg of liver (wet weight) are required for Cu quantitation using atomic absorption spectrometry. This amount equates to 1 full 14 G (2-cm long) needle biopsy specimen or half of a 5-mm laparoscopic biopsy specimen. A full length 18 G needle biopsy provides only 3–5 mg of liver tissue²⁵⁵ and Cu measurement will be erroneously low.²⁶³

The consensus panel recommends the following for hepatic biopsy specimen acquisition: a minimum of 5 laparoscopic or surgical biopsy specimens from at least 2 liver lobes should be obtained for histopathology (3), aerobic and anaerobic culture (1) and quantitative Cu analysis (1). If needle biopsy specimens are obtained, collecting multiple biopsy specimens using a 14 or 16 G needle will decrease sampling error. Some studies suggest that the risk of bleeding, although independent of needle gauge, increases with the number of biopsy specimens obtained.²²⁴

After biopsy, the patient should be kept quiet and closely monitored for complications, especially hemorrhage. Pain medication should be given depending on the type of biopsy procedure. Vital signs (heart rate, femoral pulse quality, mucous membrane color, PCV, and blood pressure) should be monitored before the procedure and every 2 hours up until 6 hours post-biopsy. If there are no signs of hemodynamic instability and no clinically relevant decrease in PCV at that time ($>6\%$ – 10% decrease) then substantial post-biopsy hemorrhage is unlikely. If clinically relevant hemorrhage is suspected, abdominal ultrasound examination is used to identify newly accumulated effusion that may warrant sampling.

Key points related to biopsy acquisition are summarized in Table 15.

6.3 | Biopsy specimen interpretation

Biopsy specimens should be promptly placed into 10% neutral buffered formalin in at a ratio of 10:1 (fixative to tissue). No sample should be thicker than 0.5–1 cm to ensure proper fixation.^{210,255}

Small biopsy specimens (needle biopsies), generally require special handling and the use of specialized mesh cassettes to protect needle cores from fragmentation during transportation. Non-compressive sponges can be used but care should be taken to avoid distortion of tissue caused by cassette compression. Care is needed to select sponges that do not perforate the samples.

The key features of liver biopsy specimen interpretation include evaluation of inflammation, cellular injury or death, fibrosis, ductular reaction, and pigment deposition. Thorough evaluation of liver biopsy specimens requires application of several special stains in addition to hematoxylin and eosin (H&E). These enable better evaluation of remodeling, as well as Cu, iron, and connective tissue deposition (Table 16).

The type of inflammation should be characterized, (eg, neutrophilic, suppurative, lymphocytic, granulomatous, or pyogranulomatous), as these patterns can suggest underlying pathogenesis. The extent and type of the inflammation should be graded using a standardized scheme to give an activity score, or at least characterized using language that conveys lesion severity.^{1,210} The location of the inflammation within the portal tract and the lobule should be identified. The presence of interface inflammation, involving injury extending beyond the portal tract boundaries (ie, extending beyond the limiting plate), should be identified and its extent characterized. Necrosis, seen as apoptosis or lytic necrosis, can affect hepatocytes, biliary epithelium, sinusoidal endothelium, sinusoidal lining cells, and transiting inflammatory cells. The types of cells affected should be identified. The extent and distribution of cell death (eg, individual cell, massive, multifocal, centrilobular, and periportal) should be characterized and graded.²⁶⁹ Vacuolar change (eg, discrete lipid vacuoles or glycogen-type cytosolic accumulation) can coexist with CH.²⁷⁰ These changes may represent hepatocyte injury or hepatocyte response to inflammatory mediators, cytokines, or endotoxin or both.

Fibrosis is a key feature in the diagnosis of CH, because it is the main hallmark of chronicity. The location (eg, portal, centrilobular, and sinusoidal) and extent should be described using a standardized scheme or language that conveys lesion severity.^{1,269} Special stains such as Sirius red or Masson's trichrome are particularly useful to evaluate fibrosis and to ensure that fibrous septa are not overlooked. Stains for fibrous tissue and reticulin can help distinguish between new collagen synthesis and parenchymal collapse, a distinction not always straightforward in H&E stained sections. Often, but varying with etiology, fibrosis begins as expansion of the portal tract connective tissue. With time, thin septa may extend into the periportal regions and evolve into progressively thicker septa that bridge between portal tracts or to central vein regions. The final stages of fibrosis are characterized by prominent bridging septa and nodular regeneration of hepatocytes. At this point, the diagnostic term applied is cirrhosis or end-stage liver. Reticulin stain can highlight subtle structural changes

TABLE 15 Key points: Biopsy Acquisition

- The diagnosis of chronic hepatitis (CH) requires histopathologic evaluation of hepatic biopsy. Hepatic fine-needle aspiration (FNA) and cytology cannot make a definitive diagnosis of CH.
- “Conventional” coagulation parameters are unreliable indicators of the risk of hemorrhage after liver biopsy.
- Prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count, fibrinogen concentration, and PCV should be obtained before hepatic sampling to assess for high-risk patients. Obtaining a buccal mucosal bleeding time (BMBT) was essential for some panel members. Testing for von Willebrand’s disease is recommended in predisposed breeds.
- In dogs considered high risk for bleeding complications (PT/PTT > 1.5× the upper limit of normal, platelets <50 000/uL, fibrinogen concentration <100 µg/dL, and/or PCV < 30%), clinicians should exercise caution. Anticipatory arrangements for blood component therapy and prolonged monitoring for 12-24 hours post-biopsy are necessary in these patients.
- Laparoscopy is the method of choice for liver biopsy in dogs with suspected CH, as this minimally invasive method enables gross evaluation of the liver, extra-hepatic biliary system and adjacent structures, and safe acquisition of large targeted biopsies from multiple liver lobes.
- Laparotomy has similar advantages and disadvantages as laparoscopy, but is considerably more invasive with greater post-operative pain and recovery time.
- A minimum of 5 laparoscopic or surgical biopsies from at least 2 liver lobes should be obtained for histopathology (3), aerobic/anaerobic culture (1) and quantitative copper analysis (1).
- Ultrasound-guided hepatic biopsy is least invasive, but small samples sizes can compromise diagnostic accuracy. Accuracy is increased with a larger gauge needle (14 or 16) and by obtaining biopsies from multiple sites, but the latter carries a greater risk of post-biopsy hemorrhage.

such as centrilobular collapse, focal loss of parenchymal integrity, or early nodular regeneration.

Ductular reaction (ie, proliferation of small ductular structures derived from either mature biliary epithelial cells or bipotential progenitor cells) often is seen in chronic liver injury and is not necessarily indicative of biliary disease.^{271,272} It is common in many dogs with CH and also develops in LDH.^{165,177,180}

Evaluation for pathologic Cu accumulation is mandatory in dogs with CH.^{17,22} Rhodanine or rubeanic acid staining for Cu or Cu-binding proteins detects the presence, acinar distribution, and can subjectively estimate the severity of Cu accumulation. In dogs, pathologic accumulation of Cu is almost always most severe in centrilobular regions. It can advance into midzonal and periportal hepatocytes with increasing Cu accumulation. Periportal accumulation is often nonspecific and involves small amounts of Cu that are not clinically relevant. A subjective grading scale should be used to score the severity of Cu accumulation. Judging the clinical relevance of Cu accumulation involves considering its association with necrotic hepatocytes and development of small “copper granulomas.” Copper granulomas are unique macrophage aggregates integrated with lymphocytes, pigmented macrophages, variable neutrophils, and occasional plasma cells, with intralesional eosinophilic refractile Cu-protein aggregates in foamy macrophages with rhodanine staining. Semiquantitative scores

TABLE 16 Staining of biopsies from dogs with chronic hepatitis

Category	Stain	Feature stained
Required	Hematoxylin and eosin	Nuclear and cytoplasmic features
	Rhodanine/Rubeanic acid	Copper
	Picrosirius red/Masson's trichrome	Collagen
Recommended	Gordon and Sweet	Reticulin
	Perl's	Iron
	Schmorl's	Lipofuscin
Situational	Periodic Acid Schiff (PAS)/diastase	Glycogen/non-glycogen carbohydrates
	Oil Red O	Lipid
	Hall's stain	Bile
	Stains for infectious diseases, e.g; Ziehl Neelsen (acid fast), Fite's, Gomori methenamine silver (GMS), PAS, FISH	Organisms

Abbreviation: FISH, fluorescent in situ hybridization.

generated with these scoring systems have good correlation with quantitative measures and should be part of routine biopsy specimen evaluation.^{17,18,21,31} Because the amount of Cu may vary among liver lobes, pathologists should be able to identify which lobes are being evaluated histopathologically. The preparation of sections from different liver lobes on a single slide facilitates overall assessment.

Atomic absorption spectroscopy is the gold standard for quantitative assessment of hepatic Cu content and requires only a small amount (20-40 mg) of tissue for accurate determination.^{21,262} Analysis should be reported on a dry weight basis. Other analytical methods are available (inductively coupled plasma atomic emission spectroscopy^{30,273} and neutron activation analysis^{15,274,275}), but these methods require publication of additional validation. Digital quantification of Cu using scanning of rhodanine-stained biopsy sections may be the most accurate method for determination of tissue Cu, because it quantifies Cu in the rhodanine-stained tissue and can avoid variations in Cu content that occur in CH, particularly once normal lobular architecture has been distorted.²⁶²

When there are discordant results between quantitative and qualitative evaluations of hepatic Cu content, or a sample for Cu analysis was not obtained during biopsy, deparaffinized tissue from the block or fresh frozen tissue can be used to perform additional Cu analysis.²⁶³

Special stains for infectious agents can be useful in selected circumstances. Granulomatous or pyogranulomatous inflammation should prompt a search for infectious etiology. Acid fast stains for mycobacteria and periodic acid Schiff or silver stains can detect fungi. Gram staining or fluorescent in situ hybridization (FISH)^{25,51,187} can detect bacteria. Immunohistochemical staining can detect viruses and protozoa.

Saving snap-frozen samples of liver is useful for molecular techniques such as PCR.

Once the pathologist has assessed the tissue section, a morphologic diagnosis is made. A thorough pathologic assessment is facilitated by having comprehensive clinical data, multiple sites of collection of adequate tissue specimens that are properly labeled, and inclusion of gross images of the liver. An exchange of information between clinician and pathologist optimizes liver biopsy specimen interpretation. In many instances, it may be preferable to send samples from challenging cases to a pathologist with expertise in hepatic pathology.^{276,277}

Key points related to biopsy interpretations are summarized in Table 17.

7 | TREATMENT

Treatment of CH in dog should target the causative agent (Table 2). Unfortunately, CH in the dog often is often idiopathic.^{6,27,38} If thorough diagnostic investigation fails to disclose a plausible etiology, then treatment with nonspecific hepatoprotective agents (see below) with or without a trial of immunosuppressive treatment may be indicated. Immunosuppressive interventions should be based on histologic evidence of a suspected immune-mediated process.

7.1 | Infectious

Infectious hepatopathies require antimicrobial treatment. Discussion of these interventions is beyond the scope of this consensus statement and readers are referred to reviews and recent book chapters.^{278–281} In some cases, treatment of the inciting infectious agent (eg, leptosporosis) may lead to clinical remission of CH, whereas in other cases full remission may not be achieved, possibly as a result of pathogen-induced self-perpetuating immune disease.⁵¹

7.2 | Drugs and toxins

Suspected hepatotoxic drug or supplement exposure should be promptly discontinued and hepatic recovery monitored by serial biochemical evaluations. In most cases, antioxidant treatment is indicated. In dogs with histologically identified inflammatory infiltrates, short courses of an anti-inflammatory dosage of corticosteroids may be beneficial.²⁸² It is unclear whether dogs with preexisting CH are predisposed to

drug-induced liver disease. In human patients, CH is a risk factor for some drug reactions.^{283–285} Some, but not all, panel members felt that dogs with CuCH were at increased risk for nonsteroidal anti-inflammatory drug-induced liver injury.¹⁰³

7.3 | Copper-associated CH

Increased hepatic Cu concentration in a dog with CH is abnormal and should be managed. Excess hepatic Cu increases risk for oxidative membrane injury, generating injurious hydroxyl and superoxide radicals.²⁸⁶ Treatment for CuCH involves lifelong dietary Cu restriction and removal of Cu from the liver. After completion of chelation, zinc may be administered to restrict enteral Cu absorption.

Copper-restricted diets (Table 18) that provide <0.12 mg/100 kcal of Cu are recommended in all dogs with a Cu concentration >600 µg/g dw.^{11,16,17,35} Dietary Cu restriction does not replace the need for Cu chelation. Because most currently available Cu-restricted diets are modestly protein restricted, and because most dogs with CH do not require protein restriction, additional protein supplementation is advised. If dogs will not eat a commercial Cu-restricted diet, a homemade Cu-restricted diet may be formulated by a clinical nutritionist. Copper concentration of water should be <0.1 µg/g. With Cu plumbing, flushing the line for 5 minutes eliminates Cu. If bottled water is used, it should be distilled. Dietary Cu restriction is advised as lifelong management unless a point source of Cu contamination in the environment is identified.

D-penicillamine (D-Pen) is the Cu chelator of choice (Table 10). This drug binds hepatic Cu which subsequently is eliminated in urine.^{9,287,288} In addition, D-Pen increases metallothionein in hepatocytes (detoxifying intracellular Cu) and enterocytes (facilitating fecal elimination) and has mild anti-inflammatory and anti-fibrotic properties.^{288–292} D-penicillamine is given PO on an empty stomach because food substantially decreases bioavailability.²⁹³

D-penicillamine combined with dietary Cu restriction usually normalizes hepatic Cu concentrations as high as 1500 µg/g dw within 6 months. Hepatic Cu concentrations of 2000–3000 µg/kg dw typically normalize within 9 months. Higher concentrations may require longer chelation intervals. Chelation may fail or take longer if D-Pen is not given with a Cu-restricted diet. Treatment efficacy is best determined by repeat quantification of hepatic Cu concentration. Normalization of serum ALT activity is used as a surrogate to estimate treatment success. Because serum ALT activity lacks the sensitivity to determine residual mild Cu accumulation and associated hepatic damage,¹⁹⁴ treatment for 1 month after ALT activity returns to normal is recommended. It is difficult to predict the duration of chelation necessary for individual dogs.¹²

Adverse effects of D-Pen (Table 18) are mostly gastrointestinal. Strategies to combat these include gradual dose escalation, administering D-Pen with a small piece of meat, or concurrent use of antiemetics. Some panel members preferred coadministration of a short course of low-dose corticosteroids to stimulate appetite when dogs are inappetent. Other adverse effects of D-Pen are rare, with proteinuria or skin eruptions being most common. D-penicillamine may

TABLE 17 Key points: Biopsy Interpretation

- Hepatic biopsy interpretation should include a scored (mild, moderate, or severe) evaluation of type and degree of inflammation/degeneration (grade), fibrosis/nodularity (stage), as well as an evaluation of the copper staining pattern and a semiquantitative score of copper staining intensity.
- The presence of (pyo)granulomatous inflammation should prompt a search for an infectious etiology.
- An exchange of information between clinician and pathologist optimizes biopsy interpretation.

TABLE 18 Treatment of copper (Cu) associated chronic hepatitis

Treatment	Mechanism of action	Dose/duration	Formulations	Other relevant pharmacology	Adverse effects
Dietary Cu restriction	Limits Cu uptake in intestine Diet: <0.12 mg Cu/100 kcal Water: limit Cu intake in water <0.1 µg/g Flush Cu pipes for 5 minutes Bottled water should be distilled	AAFCO recommendations for Cu = 0.18 mg/100 kcal Restricted diet: 0.09–0.12 mg/100 kcal Duration: lifetime	Commercially available Cu restricted diets: Royal Canine Hepatic (St Charles, MO) Hills L/d Liver Care, (Topeka, KS) Purina HP Hepatic (Europe only), (St. Louis, MO) Homemade diet (balanced canine diet- best formulated by a clinical nutritionist)	Copper restricted diets are mildly protein restricted: 3.9–4.1 mg/100 kcal Minimal protein requirement = 4.5 mg/100 kcal	Most dogs do not need protein restriction therefore supplement commercial Cu restricted diets with protein source: 0.5–1.5 g protein/kg body weight. Copper content of alternative protein sources: https://ndb.nal.usda.gov/ndb/
D-Penicillamine	Chelates Cu, with urinary excretion Upregulates hepatic metallothionein binding intracellular Cu	10–15 mg/kg BID Administer 30 minutes before or 2 hours after a meal Treatment duration based on repeat hepatic Cu quantification or surrogate monitoring of ALT Maintenance therapy at 2–3 times weekly, once a day with a reduced dose (50%) observationally effective	Cuprimine (Bausch Health, Quebec, Canada) -DePen (Meda Pharmaceutical, Somerset, NJ) Compounded formulations in the United States	Anti-inflammatory Anti-fibrotic Co-treatment with zinc contraindicated	Common: Nausea, vomiting, hyporexia Dermatological reactions Occasional proteinuria (glomerulonephritis) Induced ALP and glycogen vacuolar hepatopathy Rare: Immunologic reactions (joint, liver) Bone marrow dyscrasia Tetratogenic Cu and Zn deficiency (rare) Pyridoxine deficiency (rare) (supplement with 10–25 mg daily) Monitor UPC, CBC and liver enzymes
Trientine	Copper chelator	5–7.5 mg/kg PO BID	Syrpine (Bausch Health, Quebec, Canada)	Prohibitively expensive	Acute kidney injury
Zinc	Interferes with enteric zinc absorption by inducing intestinal metallothionein that binds Cu Induces hepatic metallothionein	8–10 mg/kg/d of elemental zinc Decoppers slowly therefore only suitable for maintenance treatment	FDA approved: Galzin (Teva Pharmaceuticals, North Wales, PA) zinc acetate (30% zinc) OTC: zinc gluconate Gluzin (Extreme V, Lowes, DE) (13% zinc)	Monitor serum levels for effective dose: >200 µg/dL	Common: Nausea, vomiting Rare: Hemolytic anemia. Monitor serum levels for toxic dose: <800 µg/dL

Abbreviations: AAFCO, Association of American Feed Control Officials; CBC, complete blood count; FDA, Food and Drug Administration; UPC, urine protein creatinine ratio; Zn, zinc.

induce ALP activity and a mild to moderate vacuolar hepatopathy that resolves with drug discontinuation.⁴⁴ Co-treatment with D-Pen and zinc is strictly contraindicated because each negates the benefits of the other.

Because of the high cost of D-Pen products (Table 18) in the United States, the consensus panel members in the United States routinely used D-Pen compounded at specialty pharmacies and agreed that these products are effective.

Experience with alternative Cu-chelating agents such as choline tetrathiomolybdate and trientine (Table 18) in dogs is limited. Therefore, they cannot be recommended at this time.^{293–297}

Zinc interferes with enteric Cu uptake via metallothionein induction (Table 18).^{298,299} Zinc acetate decreases hepatic Cu in a small study in dogs.²⁹⁹ Zinc administration, however, decreases hepatic Cu concentrations slowly, making it inappropriate for acute interventions.³⁰⁰ One study demonstrated no additional benefit when PO zinc was combined with a Cu-restricted diet.¹⁰ Based on limited information, a zinc dosage for CuCH has been extrapolated (Table 10). Zinc must be given on an empty stomach. An over-the-counter pharmaceutical grade formulation of zinc gluconate is used in Wilson's disease and a prescription drug (zinc acetate) is also available. Plasma zinc concentrations should be measured to assure therapeutic but not toxic serum concentrations. Gastrointestinal intolerance is common and often dose limiting.

During chelation treatment, antioxidant treatment, such as S-adenosylmethionine (SAME) and vitamin E, is recommended because Cu causes oxidative liver injury (Table 19).^{113,286,300–312}

In some dogs with CuCH, severe lymphocytic hepatitis may reflect a concurrent primary process or reactive neoepitope formation provoked by oxidative injury. These dogs require immunomodulatory treatment as prescribed for those with other suspected immune-mediated necroinflammatory liver disorders. This treatment can be initiated at the time of the original diagnosis, when appropriate measures to decrease hepatic Cu fail to normalize serum ALT activity, or when repeat hepatic biopsy shows restoration of normal Cu concentrations but persistent inflammation.

Dietary Cu restriction is advised as a lifelong management strategy in any dog with CuCH. Copper-restricted diets as a solitary intervention after chelation may maintain hepatic Cu concentration in the reference range in some dogs, but this depends on client compliance and has not been studied across many different dog breeds. Some dogs need additional chronic management strategies: either chronic low-dose zinc or chronic intermittent low-dose D-Pen administration 2–3 times weekly (5–10 mg/kg PO). D-penicillamine may be effective using this dosing strategy, but this has not been studied in dogs with CuCH.

7.4 | Hepatoprotective agents and antioxidants

Necroinflammatory hepatic disease is associated with depletion of antioxidant defense mechanisms,^{172,303–307} justifying the use of cytoprotective agents with antioxidant properties (Table 19).

Ursodeoxycholic acid is a relatively hydrophilic dihydroxy secondary bile acid with choleretic, immunomodulatory, antioxidant, anti-inflammatory, cytoprotective, and antiapoptotic properties.^{308–310} It is widely prescribed for liver disease despite little investigation of its efficacy.^{311,312} This bile acid is recommended based on the benefits shown in multiple preclinical and clinical studies in humans and in animal models of liver disease (Table 11). It is indicated for dogs with CH manifesting evidence of cholestasis, inflammation involving bile ductules, and in those with suspected bile-borne bacterial infection.

S-adenosylmethionine is an intermediary metabolite essential for hepatic transsulfuration, transmethylation, and decarboxylation reactions. Because severe liver injury can downregulate the enzyme controlling methionine transformation into SAME, SAME can become a conditionally essential nutrient.^{313,314}

Hepatic transsulfuration of SAME generates glutathione (GSH), an important antioxidant in the liver. Hepatic GSH concentrations in dogs are lower compared to other species, which potentially increases their risk for oxidative injury.³⁰³ Giving SAME replenishes hepatic GSH in dogs.³¹⁵

The high reactivity of natural SAME limits its pharmacologic potential. However, stable synthetic salts with enteric coatings allow the use of PO SAME supplements. The initial formulation, a disulfonate salt, was replaced with a tosylate salt. Formation of a granular barrier with the tosylate salt yielded a non-enteric coated chewable tablet. A new generation phytate salt with enteric coating is now available. Pharmacokinetics and pharmacodynamics of the 1,4-butanedisulfonate salt and the pharmacokinetics of the granular tosylate salt were studied in dogs.^{315–317} Details of the phytate salt bioavailability have not yet been published, but it is thought to have increased bioavailability, permitting use at a lower dosage (5–10 mg/kg). Caution is advised in selecting a SAME product because many have unknown bioavailability and vary in SAME content.³¹⁸ The panel recommends SAME products from reputable manufacturers for which bioavailability and pharmacokinetics in dogs and product content have been reported.^{315,316,319–321}

Although there is strong preclinical evidence that SAME has hepatoprotective actions in vitro and in animal models of liver disease, the clinical benefit of SAME has not been rigorously investigated. A few clinical trials in humans suggest benefit in improving biochemical tests of liver function, but not in overall outcome.^{319,320} In dogs, SAME administration protected against acetaminophen hepatotoxicity and improved hepatic GSH in corticosteroid-induced vacuolar hepatopathy.^{315,321} In addition, a SAME/silymarin formulation protected against lomustine-associated hepatotoxicosis.⁹⁶ There is a need, however, for high-quality randomized placebo-controlled clinical trials in well-defined clinical populations.

Despite historical use of milk thistle derivatives (silymarin, silibinin) for liver disease in humans, and recent popularity for use in dogs with suspected liver disease, documentation of beneficial effects remains equivocal. Outcomes of in vitro and in vivo studies of silibinin are confounded by inappropriate nomenclature of different studied compounds and dose variability of active ingredients.³¹² The PO bioavailability of silymarin is low (30%–50%) and the half-life short

TABLE 19 Hepatoprotective medications used in the treatment of chronic hepatitis in dogs

Medication	Formulation	Dose	Mechanism of action	Adverse effects
S-adenosylmethionine (SAME)	Unstable compound use only stabilized salts Butanedisulfonate Tosylate Phytate	20 mg/kg PO once a day on an empty stomach Phytate salt: 8-10 mg/kg once a day ^a	Increases intracellular cysteine leading to increased hepatic glutathione synthesis Increases methylation of phospholipids and DNA which promotes membrane stability and controls production of inflammatory cytokines. Numerous other advantageous effects. Increases hepatoprotective polyamines	Rare: Nausea
Vitamin E	Alpha-tocopherol	10 IU/kg once a day PO not to exceed 400 IU per dog, given with food to increase bioavailability	Protects against lipid peroxidation Anti-fibrotic Anti-inflammatory	Overdosage: can impair vitamin K activity; may increase risk for oxidative injury because of accumulation of tocopheroxy radical
Ursodeoxycholate	Stable bile acid Use of generic encouraged 250 mg pill and 300 mg capsule	15 mg/kg once a day PO given with food to increase bioavailability	Antioxidant Choleretic Immunomodulatory Anti-inflammatory	Rare: Nausea Diarrhea Safety studies show no adverse clinical or biochemical effects. Mild effect on TSBA levels
Silymarin (milk thistle)	Active ingredients: silybin A silybin B Available complexed to phosphatidyl choline to increase bioavailability but data lacking on achieving therapeutic effect	Native extract: Dose largely undefined: 4-8 mg/kg/d given 2-3 times a day PC complexed: not well defined 0.7-6 mg/kg/d PO once a day	Antioxidant Anti-inflammatory Anti-fibrotic Choleretic	Rare: Inhibits CP450 enzymes and p-glycoprotein

Abbreviations: PC, phosphatidylcholine; TSBA, total serum bile acid.
^aPharmacologic data not published to substantiate lower dose of the phytate salt.

(4–6 hours), meaning high doses and repeated administration are necessary to obtain therapeutic concentrations.³¹² Studies of silymarin in humans, including National Institutes of Health-sponsored clinical trials using highly standardized preparations, have failed to achieve projected therapeutic endpoints.^{322–324}

Commercial formulations of silybin complexed with phosphatidylcholine have improved bioavailability (4.4-fold increase over uncomplexed extract),^{325–328} but it is unknown if this formulation achieves therapeutic relevance. A single study of complexed silymarin with SAME showed protection against lomustine-associated hepatotoxicosis in dogs.⁹⁶ Toxicity has been reported rarely. Because silymarin can inhibit certain cytochrome-p450 enzymes and p-glycoprotein, caution is warranted if high-dose silybin is used with polypharmacy protocols.³¹² Although most panel members used a combination of SAME silybin product, additional studies are needed to clarify the clinical benefit of silymarin products in dogs with CH.

α -Tocopherol (vitamin E) functions as an antioxidant protecting cell and organelle membranes (notably mitochondrial) from lipid peroxidation.^{329–332} A pilot study of dogs with CH fed a vitamin E-supplemented diet for 3 months found increased serum and hepatic vitamin E concentrations accompanied by improved GSH redox cycling, but no change in histologic features.³³³ Although all panel members use vitamin E in necroinflammatory liver disease, largely based on clinical evidence of its efficacy in certain liver diseases in humans,^{329–332} they acknowledge that there is limited study of its efficacy in CH in dogs.

7.5 | Immune-mediated hepatitis

A few studies using prednisolone, azathioprine, or cyclosporine in CH have been reported in dogs and are summarized in Table 20.^{146,162–166,334} In these reports, some dogs with CH showed improvement, inferring

TABLE 20 Summary of studies investigating anti-inflammatory/immunosuppressive treatment in dogs with chronic hepatitis

Study	Design	Breeds/numbers	Drugs	Results	Important bias
Strombeck et al (1988) ¹⁶²	Retrospective	Multiple, n = 151	Prednisone: 2.2 mg/kg PO tapered to 0.6 mg/kg over 2–3 weeks	Treatment increased survival from a median of 10m to 30m	Lots of Dobermans Dogs that died in first week excluded Lack of dose standardization Lack of copper exclusion Inclusion of drug associated disease
Favier et al (2013) ¹⁶³	Retrospective	Only idiopathic CH Multiple breeds, n = 36	Prednisolone: 1 mg/kg/d PO for 12 weeks	Complete remission in 11/36, partial response in 8/36, no response in 17/36 Histological remission in 9/36 dogs at 3 weeks	Only needle biopsy follow-up No information on diet or concurrent supportive interventions
Bayton et al (2013) ¹⁶⁴	Prospective	English Springer Spaniels, n = 14	Prednisolone: 1–2 mg/kg/d PO	Improvement in liver enzymes and bilirubin Improved survival over historical controls	Concurrent supportive interventions No follow-up biopsy
Sakai et al (2014) ³³⁴	Retrospective	Labrador Retrievers, n = 8	Prednisone Azathioprine	Median survival 630 day (21–2336) No improvement in survival over historical controls	Copper status not defined No control group No biopsy follow-up
Kanemoto et al (2013) ¹⁶⁵	Retrospective	Cocker Spaniels, n = 13	Prednisone: 0.5–1.25 mg/kg/d PO Azathioprine: 1 mg/kg/d PO	Longer survival than reported in historical controls	Concurrent supportive intervention No biopsy follow-up Variability in long-term follow-up
Ullal et al (2018) ¹⁶⁶	Retrospective	Multiple, n = 48	Cyclosporine: 5 mg/kg BID PO	76% obtained remission (normalization of ALT)	No biopsy follow-up Concurrent supportive intervention
Speeti et al (2005) ¹⁴⁹	Retrospective, necropsy	Dobermans, n = 14	Prednisolone: 0.1–0.5 mg/kg/d PO	Down regulation of MHC Class II expression	Limited to evaluation of MHC Positive copper expression

Abbreviations: ALT, alanine aminotransferase; CH, chronic hepatitis; MHC, major histocompatibility complex.

an immunomodulatory or anti-inflammatory benefit. However, it is difficult to draw general conclusions from these studies because they were done in many different breeds, used variable doses of immunosuppressive therapies with other concurrent therapies, often lacked post-treatment histology, and involvement of Cu was not standardized or quantified.

Collectively, these studies support the existence of a subset of dogs with CH that respond to immunosuppressive treatment. At present, however, not enough evidence is available to recommend an optimal immunosuppressive protocol. The following recommendations reflect the clinical observational experience of the panel without unanimous agreement regarding the best initial approach. All agreed that corticosteroids are efficacious as first-line treatment, but acknowledged the limiting impact of drug-related adverse effects (eg, catabolic effects, polyuria, polydipsia, hepatocyte glycogen vacuolation or degeneration, serum liver enzyme induction) that complicate evaluation of treatment response. Additional adverse effects are especially problematic in dogs with advanced liver injury (eg, sodium and water retention that provoke ascites, catabolism, risk for enteric ulceration that may precipitate HE, complex imbalances in coagulation leading to hypercoagulability). Some panel members combine corticosteroids with another immunosuppressive drug (either azathioprine or cyclosporine) to enable more rapid tapering of the corticosteroid administration to every other day anti-inflammatory doses. For most panelists, maintenance on the second drug alone was the goal. For other panel members, single agent cyclosporine twice a day was used as first-line treatment to avoid the adverse effects of corticosteroids. Cyclosporine is tapered to once a day as soon as remission is established. Mycophenolate also has been used with success as a first- or second-line treatment by panel members and in combination with

corticosteroids. The length of time necessary to reach remission with immunosuppressive therapy and whether or not lifelong maintenance therapy is necessary in immune mediated CH in dogs is largely undefined. Consult Table 21 for information on drug dosages, formulations, and adverse effects.

Key points associated with treatment are summarized in Table 22.

7.6 | Dietary management

No studies have investigated dietary protein requirements in dogs with CH. Based on studies in humans, protein restriction is not recommended for most dogs with CH.^{335,336} If signs of HE are suspected, feeding a prescription diet with protein restricted to 2.1-2.5 g protein/kg body weight (when consumed for maintenance energy requirements) can be a starting point. However, it is prudent to individually titrate these diets with an additional 0.25-1.5 g protein/kg body weight with protein sources that are well tolerated (dairy or vegetable [soy]). There is no need to restrict fat in dogs with CH. Vitamin K supplementation is not warranted unless a dog has acholic feces, is severely and chronically hyperbilirubinemic, or has prolongation of PT associated with hemorrhagic tendencies. Chronic over supplementation of vitamin K can impose an oxidant challenge. If a dog becomes polyuric and polydipsic or is on diuretic treatment, addition of a balanced B vitamin supplement is recommended because of risk for urinary loss of water-soluble B vitamins. Historically, sodium restriction was prescribed for human patients and thus for dogs that develop ascites. Although recommended in clinical practice guidelines, severe sodium restriction has become controversial in human hepatology because of its limited efficacy and most importantly its negative effects on diet palatability and thus nutritional state.^{337,338}

TABLE 21 Use of immunosuppressive therapy in immune hepatitis

Drug	Dose	Formulations	Adverse effects
Prednisone/ prednisolone	2 mg/kg once a day gradually tapered to 0.5 mg/kg every other day No greater than 40 mg/d/dog	No evidence that hepatic disease limits conversion of prednisone to prednisolone When ascites is present use dexamethasone (no mineralocorticoid effect) or methylprednisolone ("minimal" mineralocorticoid effect) equivalents to avoid sodium retention	Induction of liver enzymes particularly ALP and GGT Steroid hepatopathy PU/PD/PP Hypercoagulability Nausea/vomiting Catabolism Sodium retention Subclinical UTI
Azathioprine	2 mg/kg (or 50 mg/m ²) SID for 14 days then every other day	Generic formulation acceptable	Bone marrow suppression Hepatotoxicity (rare)
Cyclosporine	5 mg/kg BID tapered to once a day	Use modified cyclosporine only Atopica (Elanco, Greenfield, IN) or Neoral (East Hanover, NJ) Pharmacokinetic (trough levels) and pharmacodynamic (IL-2 suppression) may optimize dose administration	Common: Nausea/vomiting Gingival hyperplasia Rare: Hepatotoxicity Subclinical UTI Opportunistic infections
Mycophenolate	10-15 mg/kg BID	Generic formulations acceptable	Diarrhea which may be delayed

Abbreviations: ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; IL-2, interleukin 2; PD, polydipsia; PP, polydipsia; PU, polyuria; UTI, urinary tract infection.

TABLE 22 Key points: Treatment

- Copper-associated chronic hepatitis (CuCH) is treated by a multimodal approach that must include dietary copper (Cu) restriction, removal of Cu from the liver by chelation with D-Pen, and antioxidant treatment. Although treatment response is best assessed by repeat biopsy and Cu quantification, serial monitoring of serum ALT is a useful surrogate monitoring strategy. Long-term management is highly patient dependent and is achieved either with a Cu restricted diet alone, or in combination with low-dose zinc treatment or low-dose 2-3 times weekly D-penicillamine.
- There is no large body of veterinary evidence-based information to substantiate efficacy of the hepatoprotective agents ursodeoxycholate, s-adenosylmethionine (SAME), and vitamin E in chronic hepatitis (CH) in dogs. However, based on their safety profile and extensive preclinical study and investigated utility in human liver diseases, these agents are routinely used as adjunctive treatment.
- Solidifying a diagnosis of immune hepatitis may rely on assessing response to immunosuppressive treatment. The panel members have had success using corticosteroids, azathioprine, cyclosporine, and mycophenolate in single or combined treatment protocols. At present there is no designated immunomodulatory protocol that can be recommended as “standary of care” for suspected immune-mediated CH in dogs without further focused studies.

8 | PROGNOSIS

There is ample evidence that once diagnosed, histological lesions of CH progress and many dogs die from causes related to their hepatic disease. Survival times have been reported in several retrospective studies^{27,41,155,156,162,163,168,176,179} (Supporting Information Table S3). Dogs in these studies were treated with a variety of medications and diets. In the 10 studies with survival data ($n = 364$ dogs), mean survival time was 561 ± 268 days. In dogs with biopsy-proven cirrhosis, survival was considerably shorter, 23 ± 23 days ($n = 39$). Considering 2 additional studies in which survival in dogs with ascites was determined (dogs that most likely had cirrhosis), mean survival time was 22.5 ± 15 days ($n = 60$). Dogs with LDH also have shorter survival times than dogs with CH. In 2 studies ($n = 13$), survival time for dogs with LDH was 48 ± 38 days.^{27,178}

Several studies have examined prognostic factors in CH and these are summarized in Supporting Information Table S4.^{27,157,162,168,175,176,188} Clinicopathologic factors with the strongest association with poor prognosis are hyperbilirubinemia, prolongations in PT and aPTT, and hypoalbuminemia. Two studies, however, found no association between hyperbilirubinemia or low serum albumin concentrations and survival.^{162,168} Ascites and the extent of fibrosis in biopsy specimens also are associated with shorter survival time.^{27,162,176,272,339} An exception may be in Cocker Spaniels with CH where dogs with ascites can have prolonged survival.¹⁶⁵ No studies have found an association between increases in serum liver enzyme activities and survival.^{27,155,162,168}

In a single study, a clinical score that incorporates clinical signs associated with hepatic failure was significantly higher in dogs with poor short-term survival and was correlated with overall survival time.¹⁶⁸ Additional studies validating a clinical scoring system are

TABLE 23 Key points: Prognosis

- Once diagnosed with chronic hepatitis (CH), histological lesions progress, and many dogs die from causes related to their hepatic disease.
- Survival times with a diagnosis of cirrhosis or lobular dissecting hepatitis (LDH) are short (1-2 months).
- Factors with the strongest association with poor prognosis are hyperbilirubinemia, prolongations in prothrombin time (PT) and activated partial thromboplastin time (aPTT), hypoalbuminemia, the presence of ascites and the degree of fibrosis on biopsy.

necessary in CH in dogs before this clinical score should be used extensively.

Key points related to prognosis are summarized in Table 23.

9 | COMPLICATIONS

The complications associated with CH in dogs are listed in Supporting Information Table S5 and include PH, ascites, HE, coagulation disorders, infection, and gastroduodenal ulceration.^{232,340-345} Additional complications reported in humans with CH include hepatopulmonary syndrome, hepatorenal syndrome, spontaneous bacterial peritonitis, and hypersplenism. Although a clinical scenario resembling hepatopulmonary syndrome recently has been described in dogs with CH, the other complications have not been reported in dogs.³⁴⁶⁻³⁴⁹

9.1 | Portal hypertension

A full discussion of the pathophysiology of PH is beyond the scope of this consensus statement and the reader is referred to recent reviews.^{340,341} Potential noninvasive markers of increased portal vein pressure (PVP) in dogs with CH include measurement of plasma endothelin concentrations and determination of portal vein-to-aortic ratio using CT angiography.^{350,351} The presence of PH in dogs usually is inferred by recognition of its clinical consequences (Table 24), by assessment of portal vein hemodynamics with Doppler ultrasound or both.³⁴¹

To date, the value of measuring and monitoring of PH in dogs has not been investigated, although in humans, control of PVP is an important therapeutic endpoint to avoid complications associated with PH.^{352,353} Because no drugs are known to modulate PVP in dogs, treatment is aimed primarily at factors that aggravate PH (eg, hypervolemia, sodium loading) and mitigating the consequence of PH (eg, ascites, HE, gastrointestinal ulceration, enteric hemorrhage).

9.2 | Ascites

Analysis of ascitic fluid accompanying PH associated with CH or cirrhosis typically demonstrates low protein concentration (<2.5 g/dL) characteristic of a pure or modified transudate. Treatment of ascites requires establishment of natriuresis, usually by avoidance of sodium

TABLE 24 Inferred diagnosis of portal hypertension

Parameter	Change with portal hypertension
Clinical signs	Ascites Neurologic signs compatible with hepatic encephalopathy Pale mucous membranes
Suggestive clinical pathology	+/- Anemia Microcytosis Hyperammonemia Increased total serum bile acids Ascites: pure or modified transudate Decreased protein C activity
Ultrasound	Detection of APSS Decreased velocity or portal vein blood flow Hepatofugal flow in portal vein Portal vein/aortic <0.65 in the absence of a single CPSS

Abbreviation: APSS, acquired portosystemic shunts; CPSS, single congenital portosystemic shunt.

loading, diuretic use, and paracentesis.^{337,338,340,341,354} These strategies are summarized in Supporting Information Table S5.

Diuretics are recommended in addition to avoidance of high sodium foods. The diuretic of choice is the aldosterone antagonist, spironolactone. Spironolactone works slowly to mobilize fluid and the dose can be titrated slowly to effect. Addition of low-dose furosemide also facilitates establishment of natriuresis. Diuretic dosages are tapered to the lowest effective dosage with careful patient monitoring (ie, daily weight, abdominal girth assessments, PCV, serum creatinine, albumin, and electrolyte concentrations), and should be discontinued or reevaluated in the event of hyponatremia, hypokalemia, azotemia, or development or worsening signs of HE. Abdominal paracentesis may be necessary initially or intermittently if tense ascites causes discomfort, tachypnea, or appears to be limiting splanchnic perfusion.

9.3 | Hepatic encephalopathy

The diagnosis of HE is based on the presence of neurologic signs such as lethargy, ataxia, behavioral changes, changes in mentation (eg, stupor, obtundation, and coma), head pressing, blindness, circling, shaking, twitching, and ptialism.^{205,343,344} Clinical signs of mild HE can be nonspecific (lethargy) and can easily be attributed to many other conditions. Hyperammonemia aids in the diagnosis of HE, but normal blood ammonia concentration does not eliminate the presence of HE. Evidence supports that HE is a pro-inflammatory, pro-oxidant, and hypercoagulable state.^{190,251,343,344} Treatment of HE consists of dietary protein modulation, lactulose, and antibiotics, and is summarized in Supporting Information Table S5. Recent reviews can be consulted.^{340,341,343,344} Investigation, recognition, and elimination of factors that precipitate HE, such as metabolic alkalosis, infection, increased protein load (eg, gastrointestinal bleeding, high protein meals), and synergistic neuroinhibition with sedative and analgesics is essential.

TABLE 25 Key points: Complications

- Most complications in chronic hepatitis (CH) are associated with advanced disease, and include portal hypertension, the development of acquired portosystemic shunts (APSS), hepatic encephalopathy (HE), ascites, and occasionally gastrointestinal ulceration.
- Coagulopathies accompanying hepatic disease are complex and can be marked by hyper or hypocoagulable states.
- Secondary bacterial infection appears to be rare in CH in dogs.

9.4 | Gastroduodenal ulceration

Hepatic disease is a risk factor for gastrointestinal ulceration.^{241,242,355} Although the pathophysiology is poorly understood, it does not appear to be associated with hypergastrinemia.³⁵⁶ Splanchnic congestion and poor blood flow may contribute. Enteric bleeding (melena, hematochezia) appears to be more common with advanced disease. Gastro-duodenal ulceration is treated by using antisecretory drugs, and cytoprotectants, as well as by avoiding of ulcerogenic medications (Supporting Information Table S5).

9.5 | Coagulation

Spontaneous bleeding is rare with CH in dogs, but it can occur especially in late-stage disease, manifested primarily as enteric hemorrhage.^{157,168,185} When spontaneous or procedure-induced bleeding occurs, treatment with blood products (FFP, packed red blood cells, or whole blood), anti-proteases, vitamin K, DDAVP, or some combination of these may be indicated depending on the situation, but there is poor documentation of the effectiveness of these interventions (Supporting Information Table S5). Administration of stored blood may provoke HE in some dogs.

Thrombotic complications, most notably PVT, occur in some dogs with CH.²²¹ Most dogs with PVT have at least 1 additional predisposing factor for thrombosis, the most common being corticosteroid use.

TABLE 26 Key points: Future Perspectives

- Validation of grading and staging systems for hepatic biopsy in dogs with chronic hepatitis (CH).
- Biomarkers for detection of hepatic inflammation, immune-mediated hepatitis, and copper-associated chronic hepatitis (CuCH).
- Prospective clinical trials to study the pharmacology, pharmacodynamics, and efficacy of immunosuppressive protocols in dogs with suspected immune hepatitis.
- Define the role of infectious agents as direct pathogens versus triggers for immune hepatitis.
- Address the accumulating body of evidence that high dietary copper levels are casually associated with copper induced liver damage.
- Genome-wide sequencing studies to clarify the impact of genotypes with phenotypic severity of CuCH in dogs with suspected breed predilection.
- Expand clinical assessment of coagulation status in dogs with CH to establish standard of care assessment tests that are most predictive of liver biopsy provoked hemorrhage.
- Determine a standard of care for interventional control of coagulopathies in dogs with CH.

The presence of ascites, abdominal pain, and thrombocytopenia should arouse suspicion for an acute PVT. Chronically stabilized PVT may present with minimal clinical features if APSS are established. The use of anticoagulants in dogs with PVT and CH has largely been unexplored, but dogs with acute thrombosis may benefit.²²¹

9.6 | Infection

The incidence of secondary bacterial infection is poorly documented in dogs with CH. In the 3 studies that report results of bacterial culture of the liver, cultures were positive in 0, 4.8, and 15% of dogs.^{168,183,356} Additional studies are necessary.

Key points related to complications are summarized in Table 25

9.7 | Future perspectives

During the writing of this document, the consensus panel identified critical areas of future research in CH in dogs. These are outlined in Table 26.

CONFLICT OF INTEREST DECLARATION

D. Twedt has consulted and received speaker honoraria for Nestle Purina. P. Watson has received speaker honoraria for the 2018 ACVIM Forum, Seattle, Washington, and the 2018 ECVIM-CA Congress, Rotterdam, the Netherlands.

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

Authors declare no IACUC or other approval was needed.

HUMAN ETHICS APPROVAL DECLARATION

Authors declare human ethics approval was not needed for this study.

ORCID

Sharon A. Center  <https://orcid.org/0000-0001-5598-2898>

REFERENCES

1. van den Ingh TSGAM, Van Winkle TJ, Cullen JM, et al. Morphological classification of parenchymal disorders of the canine and feline liver: hepatocellular death, hepatitis, and cirrhosis-2 (updated version). *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases*. Society of Comparative Hepatology; 2006. <http://www.vetvisuals.com/lms/moodle/mod/book/view.php?id=1001&chapterid=52859>.
2. Cullen JM. Summary of the World Small Animal Veterinary Association standardization committee guide to classification of liver disease in dogs and cats. *Vet Clin North Am Small Anim Pract*. 2009;39:395-418.
3. Meyer DJ, Twedt DC. Effect of extrahepatic disease on the liver. In: Bonagura J, ed. *Current Veterinary Therapy XIII*. Philadelphia, PA: WB Saunders; 2000:668-671.
4. Neumann S, Danner W. Reactive hepatitis in dogs. *Global Veterinaria*. 2012;9:454-459.
5. Twedt DC. Reactive hepatopathies and chronic hepatitis in the dog. *Vet Q*. 1998;2:S46-S47.
6. Bexfield N. Canine idiopathic chronic hepatitis. *Vet Clin North Am Small Anim Pract*. 2017;47:645-663.
7. Crawford MA, Schall WD, Jensen RK, Tasker JB. Chronic active hepatitis in 26 Doberman Pinschers. *J Am Vet Med Assoc*. 1985;187:1343-1350.
8. Fieten H, Hooijer-Nouwens BD, Biourge VC, et al. Association of dietary copper and zinc levels with hepatic copper and zinc concentration in Labrador Retrievers. *J Vet Intern Med*. 2012;26:1274-1280.
9. Fieten H, Hugen S, van den Ingh TS, et al. Urinary excretion of copper, zinc and iron with and without D-penicillamine administration in relation to hepatic copper concentration in dogs. *Vet J*. 2013;197:468-473.
10. Fieten H, Dirksen K, van den Ingh TS, et al. D-penicillamine treatment of copper-associated hepatitis in Labrador Retrievers. *Vet J*. 2013;196:522-527.
11. Fieten H, Biourge VC, Watson AL, Leegwater PAJ, van den Ingh TSGAM, Rothuizen J. Nutritional management of inherited copper-associated hepatitis in the Labrador Retriever. *Vet J*. 2014;199:429-433.
12. Fieten H, Biourge VC, Watson AL, Leegwater PAJ, van den Ingh TSGAM, Rothuizen J. Dietary management of Labrador Retrievers with subclinical hepatic copper accumulation. *J Vet Intern Med*. 2015;29:822-827.
13. Fieten H, Gill Y, Martin AJ, et al. The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador Retrievers: a new canine model for copper-metabolism disorders. *Dis Model Mech*. 2016;9:25-38.
14. Hoffmann G, Heuven HC, Leegwater PA, et al. Heritabilities of copper-accumulating traits in Labrador Retrievers. *Anim Genet*. 2008;39:454.
15. Hoffmann G, van den Ingh TS, Bode P, et al. Copper-associated chronic hepatitis in Labrador Retrievers. *J Vet Intern Med*. 2006;20:856-861.
16. Hoffmann G, Jones PG, Biourge V, et al. Dietary management of hepatic copper accumulation in Labrador Retrievers. *J Vet Intern Med*. 2009;23:957-963.
17. Hoffmann G. Copper-associated liver diseases. *Vet Clin North Am Small Anim Pract*. 2009;39:489-511.
18. Johnson GF, Sternlieb I, Twedt DC, Grushoff PS, Scheinberg I. Inheritance of copper toxicosis in Bedlington Terriers. *Am J Vet Res*. 1980;41:1865-1866.
19. Johnson GF, Gilbertson SR, Goldfischer S, Grushoff PS, Sternlieb I. Cytochemical detection of inherited copper toxicosis of Bedlington Terriers. *Vet Pathol*. 1984;21:57-60.
20. Johnson GF, Zawie DA, Gilbertson SR, Sternlieb I. Chronic active hepatitis in Doberman Pinschers. *J Am Vet Med Assoc*. 1982;180:1438-1442.
21. Johnston AN, Center SA, McDonough SP, et al. Hepatic copper concentrations in Labrador Retrievers with and without chronic hepatitis: 72 cases (1980-2010). *J Am Vet Med Assoc*. 2013;242:372-380.
22. Dirksen K, Fieten H. Canine copper-associated hepatitis. *Vet Clin North Am Small Anim Pract*. 2017;47:631-644.

23. Bosje JT, van den Ingh TS, Fennema A, et al. Copper-induced hepatitis in an Anatolian Shepherd dog. *Vet Rec.* 2003;152:84-85.
24. Hultgren BD, Stevens JB, Hardy RM. Inherited, chronic, progressive hepatic degeneration in Bedlington Terriers with increased liver copper concentrations: clinical and pathologic observations and comparison with other copper-associated liver diseases. *Am J Vet Res.* 1986; 47:365-377.
25. Hutchins RG, Breitschwerdt EB, Cullen JM, Bissett SA, Gookin JL. Limited yield of diagnoses of intrahepatic infectious causes of canine granulomatous hepatitis from archival liver tissue. *J Vet Diagn Invest.* 2012;24:888-894.
26. Hyun C, Filippich LJ. Inherited canine copper toxicosis in Australian Bedlington Terriers. *J Vet Sci.* 2004;5:19-28.
27. Poldervaart JH, Favier RP, Penning LC, van den Ingh TSGAM, Rothuizen J. Primary hepatitis in dogs: a retrospective review (2002-2006). *J Vet Intern Med.* 2009;23:72-80.
28. Rifkin J, Miller MD. Copper-associated hepatitis in a Pembroke Welsh Corgi. *Can Vet J.* 2014;55:573-576.
29. Robertson HM, Studdert VP, Reuter RE. Inherited copper toxicosis in Bedlington Terriers. *Aust Vet J.* 1983;60:235-238.
30. Smedley R, Mullaney T, Rumbelha W. Copper-associated hepatitis in Labrador Retrievers. *Vet Pathol.* 2009;46:484-490.
31. Thornburg LP, Beissenherz M, Dolan M, Raisbeck MF. Histochemical demonstration of copper and copper-associated protein in the canine liver. *Vet Pathol.* 1985;22:327-332.
32. Thornburg LP, Shaw D, Dolan M, et al. Hereditary copper toxicosis in West Highland White Terriers. *Vet Pathol.* 1986;23:148-145.
33. Thornburg LP, Rottinghaus G, McGowan M, Kupka K, Crawford S, Forbes S. Hepatic copper concentrations in purebred and mixed-breed dogs. *Vet Pathol.* 1990;27:81-88.
34. Thornburg LP, Rottinghaus G, Dennis G, Crawford S. The relationship between hepatic copper content and morphologic changes in the liver of West Highland White Terriers. *Vet Pathol.* 1996;33: 656-661.
35. Twedt DC, Sternlieb I, Gilbertson SR. Clinical, morphologic, and chemical studies on copper toxicosis of Bedlington Terriers. *J Am Vet Med Assoc.* 1979;175:269-275.
36. van den Ingh TS, Punte PM, Hoogendijk EN, et al. Possible nutritionally induced copper-associated chronic hepatitis in two dogs. *Vet Rec.* 2007;161:728-729.
37. Watson AD, Middleton DJ, Ilkiw JE. Copper storage disease with intravascular haemolysis in a Bedlington Terrier. *Aust Vet J.* 1983;60: 305-307.
38. Watson P. Canine breed-specific hepatopathies. *Vet Clin North Am Small Anim Pract.* 2017;47:665-682.
39. Webb CB, Twedt DC, Meyer DJ. Copper-associated liver disease in Dalmatians: a review of 10 dogs (1998-2001). *J Vet Intern Med.* 2002;16:665-668.
40. Noaker LJ, Washabau RJ, Detrisac CJ, et al. Copper associated acute hepatic failure in a dog. *J Am Vet Med Assoc.* 1999;214:1502-1506.
41. Cooper VL, Carlson MP, Jacobson J, Schneider NR. Hepatitis and increased copper levels in a Dalmatian. *J Vet Diagn Invest.* 1997;9: 201-203.
42. Mandigers PJ, van den Ingh TS, Bode P, et al. Association between liver copper concentration and subclinical hepatitis in Doberman Pinschers. *J Vet Intern Med.* 2004;18:647-650.
43. Mandigers PJ, van den Ingh TS, Bode P, et al. Improvement in liver pathology after 4 months of D-penicillamine in 5 Doberman Pinschers with subclinical hepatitis. *J Vet Intern Med.* 2005;19: 40-43.
44. Mandigers PJ, Bode P, van Wees AM, et al. Hepatic (64) Cu excretion in Dobermanns with subclinical hepatitis. *Res Vet Sci.* 2007;83: 204-209.
45. Mandigers PJ, van den Ingh TS, Spee B, et al. Chronic hepatitis in Doberman Pinschers. A review. *Vet Q.* 2004;26:98-106.
46. Strickland JM, Buchweitz JP, Smedley RC, et al. Hepatic copper concentrations in 546 dogs (1982-2015). *J Vet Intern Med.* 2018;32: 1943-1950.
47. Kroeze EJ, Zentek J, Edixhoven-Bosdijk A, et al. Transient erythropoietic protoporphyria associated with chronic hepatitis and cirrhosis in a cohort of German Shepherd dogs. *Vet Rec.* 2006;158: 120-124.
48. Sevelius E, Andersson M, Jönsson L. Hepatic accumulation of alpha-1-antitrypsin in chronic liver disease in the dog. *J Comp Pathol.* 1994;111:401-412.
49. Bishop L, Strandberg JD, Adams RJ, Brownstein DG, Patterson R. Chronic active hepatitis in dogs associated with leptospires. *Am J Vet Res.* 1979;40:839-844.
50. Adamus C, Buggin-Daubié M, Izembart A, et al. Chronic hepatitis associated with leptospiral infection in vaccinated beagles. *J Comp Pathol.* 1997;117:311-312.
51. McCallum KE, Constantino-Casas F, Cullen JM, et al. Hepatic leptospiral infections in dogs without obvious renal involvement. *J Vet Intern Med.* 2019;33(1):141-150.
52. Gonzales JL, Rollan E, Novoa C, et al. Structural and ultrastructural hepatic changes in experimental canine leishmaniasis. *Histol Histopathol.* 1988;3:323-329.
53. Rallis T, Day MJ, Saridomichelakis MN, et al. Chronic hepatitis associated with canine leishmaniasis (*Leishmania infantum*): a clinicopathological study of 26 cases. *J Comp Pathol.* 2005;132: 145-152.
54. Egenvall A, Bjöersdorff A, Lilliehöök I, et al. Early manifestations of granulocytic ehrlichiosis in dogs inoculated experimentally with a Swedish Ehrlichia species isolate. *Vet Rec.* 1998;143:412-417.
55. Mylonakis ME, Kritsepi-Konstantinou M, Dumler JS, et al. Severe hepatitis associated with acute *Ehrlichia canis* infection in a dog. *J Vet Intern Med.* 2010;24:633-638.
56. Frank JR, Breitschwerdt EB. A retrospective study of ehrlichiosis in 62 dogs from North Carolina and Virginia. *J Vet Intern Med.* 1999;13: 194-201.
57. Harrus S, Kass PH, Klement E, Waner T. Canine monocytic ehrlichiosis: a retrospective study of 100 cases, and an epidemiological investigation of prognostic indicators for the disease. *Vet Rec.* 1997;141: 360-363.
58. Nair AD, Cheng C, Ganta CK, et al. Comparative experimental infection study in dogs with *Ehrlichia canis*, *E. chaffeensis*, *Anaplasma platys* and *A. phagocytophilum*. *PLoS One.* 2016;11:e0148239.
59. Hildebrandt PK, Huxsoll DL, Walker JS, Nims RM, Taylor R, Andrews M. Pathology of canine monocytic ehrlichiosis (tropical canine pancytopenia). *Am J Vet Res.* 1973;34:1309-1320.
60. de Castro MB, Machado RZ, de Aquino LP, et al. Experimental acute canine monocytic ehrlichiosis: clinicopathological and immunopathological findings. *Vet Parasitol.* 2004;119:73-86.
61. Campora L, Corazza M, Zullino C, Ebani VV, Abramo F. *Mycobacterium avium* subspecies hominissus disseminated infection in a Bas-set Hound dog. *J Vet Diagn Invest.* 2011;23:1083-1087.
62. Martinho AP, Franco MM, Ribeiro MG, et al. Disseminated *Mycobacterium tuberculosis* infection in a dog. *Am J Trop Med Hyg.* 2013;88 (3):596-600.
63. Naughton JF, Mealey KL, Wardrop KJ, Oaks JL, Bradway DS. Systemic *Mycobacterium avium* infection in a dog diagnosed by polymerase chain reaction analysis of buffy coat. *J Am Anim Hosp Assoc.* 2005;41:128-132.
64. Turinelli V, Ledieu D, Guilbaud L, Marchal T, Magnol JP, Fournel-Fleury C. *Mycobacterium tuberculosis* infection in a dog from Africa. *Vet Clin Pathol.* 2004;33:177-181.
65. Rocha VC, Figueiredo SC, Rosales CA, et al. Infection by *Mycobacterium bovis* in a dog from Brazil. *Braz J Microbiol.* 2017;48:109-112.

66. Chapman BL, Hendrick MJ, Washabau RJ. Granulomatous hepatitis in dogs: nine cases (1987-1990). *J Am Vet Med Assoc.* 1993;203:680-684.
67. Brömel C, Sykes JE. Histoplasmosis in dogs and cats. *Clin Tech Small Anim Pract.* 2005;20:227-232.
68. Allison R, Williams P, Lansdowne J, Lappin M, Jensen T, Lindsay D. Fatal hepatic sarcocystosis in a puppy with eosinophilia and eosinophilic peritoneal effusion. *Vet Clin Pathol.* 2006;35:353-357.
69. Dubey JP, Chapman JL, Rosenthal BM, Mense M, Schueler RL. Clinical *Sarcocystis neurona*, *Sarcocystis canis*, *Toxoplasma gondii*, and *Neospora caninum* infections in dogs. *Vet Parasitol.* 2006;137:36-49.
70. Fry DR, McSporran KD, Ellis JT, et al. Protozoal hepatitis associated with immunosuppressive therapy in a dog. *J Vet Intern Med.* 2009;23:366-368.
71. Hoon-Hanks LL, Regan D, Dubey JP, Carol Porter M, Duncan CG. Hepatic neosporosis in a dog treated for pemphigus foliaceus. *J Vet Diagn Invest.* 2013;25:807-810.
72. Magaña A, Sánchez F, Villa K, Rivera L, Morales E. Systemic neosporosis in a dog treated for immune-mediated thrombocytopenia and hemolytic anemia. *Vet Clin Pathol.* 2015;44:592-596.
73. Dubey JP, Sykes JE, Shelton GD, et al. *Sarcocystis caninum* and *Sarcocystis svanaei* n. spp. (Apicomplexa: Sarcocystidae) associated with severe myositis and hepatitis in the domestic dog (*Canis familiaris*). *J Eukaryot Microbiol.* 2015;62:307-317.
74. Gillespie TN, Washabau RJ, Goldschmidt MH, Cullen JM, Rogala AR, Breitschwerdt EB. Detection of *Bartonella henselae* and *Bartonella clarridgeiae* DNA in hepatic specimens from two dogs with hepatic disease. *J Am Vet Med Assoc.* 2003;222:47-51.
75. Saunders GK, Monroe WE. Systemic granulomatous disease and siametaplasia in a dog with *Bartonella* infection. *Vet Pathol.* 2006;43:391-392.
76. Bexfield NH, Watson PJ, Heaney J, et al. Canine hepatitis virus is not associated with chronic liver disease in dogs. *J Viral Hepat.* 2014;24:223-228.
77. Boomkins SY, Slump E, Egberink HF, et al. PCR screening for candidate etiological agents of canine hepatitis. *Vet Microbiol.* 2005;108:49-55.
78. Rakich PM, Prasse KW, Lukert PD, Cornelius LM. Immunohistochemical detection of canine adenovirus in paraffin sections of liver. *Vet Pathol.* 1986;23:478-484.
79. van der Laan LJ, de Ruiter PE, van Gils IM, et al. Canine hepatitis virus and idiopathic hepatitis in dogs from a Dutch cohort. *J Viral Hepat.* 2014;21:894-896.
80. Chouinard L, Martineau D, Forget C, Girard C. Use of polymerase chain reaction and immunohistochemistry for detection of canine adenovirus type 1 in formalin-fixed, paraffin-embedded liver of dogs with chronic hepatitis or cirrhosis. *J Vet Diagn Invest.* 1998;10:320-325.
81. Glock DJ, Morris TQ, Bradley SE. Chronic hepatitis in the dog: the role of immune factors. *J Am Vet Med Assoc.* 1970;156:1700-1705.
82. Boschert KR, Allison N, Allen TL, Griffin RB. *Bacillus piliformis* infection in an adult dog. *J Am Vet Med Assoc.* 1988;192:791-792.
83. Wozniak EJ, Barr BC, Thomford JW, et al. Clinical, anatomic, and immunopathologic characterization of *Babesia gibsoni* infection in the domestic dog (*Canis familiaris*). *J Parasitol.* 1997;83:692-629.
84. Chirek A, Silaghi C, Pfister K, Kohn B. Granulocytic anaplasmosis in 63 dogs: clinical signs, laboratory results, therapy and course of disease. *J Small Anim Pract.* 2018;59:112-120.
85. Cook S, Priestnall SL, Blake D, Meeson RL. Angiostrongylus vasorum causing severe granulomatous hepatitis with concurrent multiple acquired PSS. *J Am Anim Hosp Assoc.* 2015;51:320-324.
86. Corapi WV, Ajithdoss DK, Snowden KF, Spaulding KA. Multi-organ involvement of *Heterobilharzia americana* infection in a dog presented for systemic mineralization. *J Vet Diagn Invest.* 2011;23:826-831.
87. Fabrick C, Bugbee A, Fosgate G. Clinical features and outcome of *Heterobilharzia americana* infection in dogs. *J Vet Intern Med.* 2010;24:140-144.
88. Flowers JR, Hammerberg B, Wood SL, et al. *Heterobilharzia americana* infection in a dog. *J Am Vet Med Assoc.* 2002;220:193-196.
89. Bunch SE. Hepatotoxicity associated with pharmacologic agents in dogs and cats. *Vet Clin North Am Small Anim Pract.* 1993;23:659-670.
90. Dayrell-Hart B, Steinberg SA, VanWinkle TJ, Farnbach GC. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989). *J Am Vet Med Assoc.* 1991;199:1060-1066.
91. Gaskill CL, Miller LM, Mattoon JS, et al. Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. *Vet Pathol.* 2005;42:147-146.
92. Müller PB, Taboada J, Hosgood G, et al. Effects of long-term phenobarbital treatment on the liver in dogs. *J Vet Intern Med.* 2000;14:165-171.
93. March PA, Hillier A, Weisbrode SE, et al. Superficial necrolytic dermatitis in 11 dogs with a history of phenobarbital administration (1995-2002). *J Vet Intern Med.* 2004;14:65-74.
94. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. *J Vet Intern Med.* 2004;18:75-80.
95. Heading KL, Brockley LK, Bennett PF. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). *Aust Vet J.* 2011;89:109-116.
96. Skorupski KA, Hammond GM, Irish AM, et al. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. *J Vet Intern Med.* 2011;25:838-845.
97. Albretsen JC, Khan SA, Richardson JA. Cycad palm toxicosis in dogs: 60 cases (1987-1997). *J Am Vet Med Assoc.* 1998;213:99-101.
98. Clarke C, Burney D. Cycad palm toxicosis in 14 dogs from Texas. *J Am Anim Hosp Assoc.* 2017;53:159-166.
99. Dereszynski DM, Center SA, Randolph JF, et al. Clinical and clinicopathologic features of dogs that consumed foodborne hepatotoxic aflatoxins: 72 cases (2005-2006). *J Am Vet Med Assoc.* 2008;232:1329-1337.
100. Ferguson D, Crowe M, McLaughlin L, Gaschen F. Survival and prognostic indicators for cycad intoxication in dogs. *J Vet Intern Med.* 2011;25:831-837.
101. Jacobs G, Calvert C, Kraus M. Hepatopathy in 4 dogs treated with amiodarone. *J Vet Intern Med.* 2000;14:96-99.
102. Kraus MS, Thomason JD, Fallaw TL, Calvert CA. Toxicity in Doberman Pinchers with ventricular arrhythmias treated with amiodarone (1996-2005). *J Vet Intern Med.* 2009;23:1-6.
103. MacPhail CM, Lappin MR, Meyer DJ, Smith SG, Webster CR, Armstrong PJ. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. *J Am Vet Med Assoc.* 1998;212:1895-1901.
104. Newman SJ, Smith JR, Stenske KA, et al. Aflatoxicosis in nine dogs after exposure to contaminated commercial dog food. *J Vet Diagn Invest.* 2007;19:168-175.
105. Vaden SL, Bunch SE, Duncan DE, Cullen JM. Hepatotoxicosis associated with heartworm/hookworm preventive medication in a dog. *J Am Vet Med Assoc.* 1988;192:651-654.
106. Wouters AT, Casagrande RA, Wouters F, et al. An outbreak of aflatoxin poisoning in dogs associated with aflatoxin B1-contaminated maize products. *J Vet Diagn Invest.* 2013;25:282-287.
107. Ganger DR, Rule J, Rakela J, Bass N, et al. Acute liver failure of indeterminate etiology: a comprehensive systematic approach by an expert committee to establish causality. *Am J Gastroenterol.* 2018;113:1319-1328.
108. Navarro VJ, Seeff LB. Liver injury induced by herbal complementary and alternative medicine. *Clin Liver Dis.* 2013;17:715-735.

109. Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. *Gastroenterology*. 2015;148:517-532.
110. Cerda C, Bruguera M, Parés A. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. *World J Gastroenterol*. 2013;19:5381-5384.
111. Khan SA, McLean MK, Gwaltney-Brant S. Accidental overdosage of joint supplements in dogs. *J Am Vet Med Assoc*. 2010;236:509-510.
112. Sokol RJ, Twedt D, McKim JM Jr, et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington Terriers with copper toxicosis. *Gastroenterology*. 1994;107:1788-1798.
113. Nagasaka H, Inoue I, Inui A, et al. Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. *Pediatr Res*. 2006;60:472-477.
114. Fedoseienko A, Bartuzi P, van de Sluis B. Functional understanding of the versatile protein copper metabolism MURR1 domain 1 (COMMD1) in copper homeostasis. *Ann N Y Acad Sci*. 2014;1314:6-14.
115. Klomp AE, van de Sluis B, Klomp LW, et al. The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis. *J Hepatol*. 2003;39:703-709.
116. Van de Sluis B, Rothuizen J, Pearson PL, et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. *Hum Mol Genet*. 2002;11:165-173.
117. Haywood S, Boursnell M, Loughran MJ, et al. Copper toxicosis in non-COMMD1 Bedlington Terriers is associated with metal transport gene ABCA12. *J Trace Elem Med Biol*. 2016;35:83-89.
118. Azumi N. Copper and liver injury-experimental studies on the dogs with biliary obstruction and copper loading. *Hokkaido Igaku Zasshi*. 1982;57:331-349.
119. Spee B, Arends B, van den Ingh TS, et al. Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver diseases in dogs. *J Vet Intern Med*. 2006;20:1085-1109.
120. Gagne JW, Wakshlag JJ, Center SA, et al. Evaluation of calcium, phosphorus, and selected trace mineral status in commercially available dry foods formulated for dogs. *J Am Vet Med Assoc*. 2013;243:658-666.
121. Cedeño Y, López-Alonso M, Miranda M. Hepatic concentrations of copper and other metals in dogs with and without chronic hepatitis. *J Small Anim Pract*. 2016;57:703-709.
122. Association of American Feed Control Officials. Official Publication, Oxford, IN: AAFCO; 2018
123. Subcommittee on Dog and Cat Nutrition, Committee on Animal Nutrition, National Research Council. *Nutrient Requirements of Dogs and Cats*. Washington, DC: The National Academy Press; 2006.
124. Stowe HD, Lawler DF, Kealy RD. Antioxidant status of pair-fed Labrador Retrievers is affected by diet restriction and aging. *J Nutr*. 2006;136:1844-1848.
125. Czarnecki-Maulden G, Rudnick R, Chausow D. Copper bioavailability and requirement in the dog: comparison of copper oxide and copper sulfate. *FASEB J*. 1993;7:A305.
126. Ammerman CB, Miller SM. Biological availability of minor mineral ions: a review. *J Anim Sci*. 1972;35:681-694.
127. Baker DH. Cupric oxide should not be used as a copper supplement for either animals or humans. *J Nutr*. 1999;129:2278-2279.
128. Su LC, Ravanshad S, Owen CA, et al. A comparison of copper-loading disease in Bedlington Terriers and Wilson's disease in humans. *Am J Physiol*. 1982;243:G226-G230.
129. Thornburg LP. A perspective on copper and liver disease in the dog. *J Vet Diagn Invest*. 2000;12:101-110.
130. Kastenmayer P, Czarnecki-Maulden GL, King W. Mineral and trace element absorption from dry dog food by dogs, determined using stable isotopes. *J Nutr*. 2002;132:1670S-1672S.
131. Gupta A, Das S, Ray K. A glimpse into the regulation of the Wilson disease protein, ATP7B, sheds light on the complexity of mammalian apical trafficking pathways. *Metallomics*. 2018;10:378-387.
132. Gromadzka G, Kruszyńska M, Wierzbicka D, et al. Gene variants encoding proteins involved in antioxidant defense system and the clinical expression of Wilson disease. *Liver Int*. 2015;35:215-222.
133. Lutsenko S. Modifying factors and phenotypic diversity in Wilson's disease. *Ann NY Acad Sci*. 2014;1315:56-63.
134. Medici V, Weiss KH. Genetic and environmental modifiers of Wilson disease. *Handb Clin Neurol*. 2017;142:35-41.
135. Appleman EH, Cianciolo R, Mosenco AS, Bounds ME, Al-Ghazlat S. Transient acquired fanconi syndrome associated with copper storage hepatopathy in 3 dogs. *J Vet Intern Med*. 2008;22:1038-1042.
136. Hill TL, Breitschwerdt EB, Cecere T, Vaden S. Concurrent hepatic copper toxicosis and Fanconi's syndrome in a dog. *J Vet Intern Med*. 2008;22:219-222.
137. Hostutler RA, DiBartola SP, Eaton KA. Transient proximal renal tubular acidosis and Fanconi syndrome in a dog. *J Am Vet Med Assoc*. 2004;224:1611-1614.
138. Langlois DK, Smedley RC, Schall WD, Kruger JM. Acquired proximal renal tubular dysfunction in 9 Labrador Retrievers with copper-associated hepatitis (2006-2012). *J Vet Intern Med*. 2013;27:491-499.
139. Lomas DA, Hurst JR, Gooptu B. Update on alpha-1 antitrypsin deficiency: new therapies. *J Hepatol*. 2016;65:413-424.
140. Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. *Gut Liver*. 2016;10:177-203.
141. Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. *J Autoimmun*. 2016;75:6-19.
142. European Association for the Study of Liver Disease. EASL Clinical Practice Guidelines: autoimmune hepatitis. *J Hepatol*. 2015;63:971-1004.
143. Alvarez F, Berg PA, Bianchi L, et al. International Autoimmune Hepatitis Group: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol*. 1999;31:929-938.
144. Hennes EM, Zeniya M, Czaja A, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology*. 2008;48:169-175.
145. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. *Hepatology*. 2010;51:2193-2221.
146. Boisclair J, Doré M, Beauchamp G, Chouinard L, Girard C. Characterization of the inflammatory infiltrate in canine chronic hepatitis. *Vet Pathol*. 2001;38:628-635.
147. Sakai M, Otani I, Ishigaki K, et al. Phenotypic analysis of hepatic T lymphocytes in a dog with chronic hepatitis. *J Vet Med Sci*. 2006;68:1219-1221.
148. Bexfield NH, Watson PJ, Aguirre-Hernandez J, et al. DLA class II alleles and haplotypes are associated with risk for and protection from chronic hepatitis in the English Springer Spaniel. *PLoS One*. 2012;7:e42584. <https://doi.org/10.1371/journal.pone.0042584>.
149. Speeti M, Ståhls A, Meri S, Westermarck E. Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis. *Vet Immunol Immunopathol*. 2003;96:1-12.
150. Dyggve H, Meri S, Spillmann T, Lohi H, Kennedy LJ, Speeti M. Evaluation of DLA promoters in Doberman hepatitis. *Tissue Antigens*. 2011;78:446-450.
151. Weiss DJ, Armstrong PJ, Mruthyunjaya A. Anti-liver membrane protein antibodies in dogs with chronic hepatitis. *J Vet Intern Med*. 1995;9:267-271.
152. Andersson M, Sevelius E. Circulating autoantibodies in dogs with chronic liver disease. *J Small Ani Pract*. 1992;33:389-394.
153. Dyggve H, Jarva H, Spillmann T, Speeti M, Meri S. Identification of glyceraldehyde-3-phosphate and alcohol dehydrogenases as autoantigens in Doberman hepatitis. *Scand J Immunol*. 2017;86:156-164.

154. Dyggve H, Meri S, Spillmann T, Jarva H, Speeti M. Antihistone auto-antibodies in Dobermans with hepatitis. *J Vet Intern Med.* 2017;31:1717-1723.
155. Speeti M, Eriksson J, Saari S, Westermarck E. Lesions of subclinical Doberman hepatitis. *Vet Pathol.* 1998;35:361-369.
156. Andersson M, Sevelius E. Breed, sex and age distribution with chronic liver disease: a demographic study. *J Small Anim Pract.* 1991;32:1-5.
157. Fuentealba C, Guest S, Haywood S, Horney B. Chronic hepatitis: a retrospective study in 34 dogs. *Can Vet J.* 1997;38:365-373.
158. Bexfield NH, Buxton RJ, Vicek TJ, et al. Breed, age and gender distribution of dogs with chronic hepatitis in the United Kingdom. *Vet J.* 2012;193:124-128.
159. Bexfield NH, Andres-Abdo C, Scase TJ, Constantino-Casas F, Watson PJ. Chronic hepatitis in the English Springer Spaniel: clinical presentation, histological description and outcome. *Vet Rec.* 2011;169:415.
160. Hirose N, Uchida K, Kanemoto H, et al. A retrospective histopathological survey on canine and feline liver diseases at the University of Tokyo between 2006 and 2012. *J Vet Med Sci.* 2014;76:1015-1020.
161. van den Ingh TS, Rothuizen J, Cupery R. Chronic active hepatitis with cirrhosis in the Doberman Pinscher. *Vet Q.* 1988;10:84-89.
162. Strombeck DR, Miller LM, Harrold D. Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977-1985). *J Am Vet Med Assoc.* 1988;193:1109-1113.
163. Favier RP, Poldervaart JH, van den Ingh TS, et al. A retrospective study of oral prednisolone treatment in canine chronic hepatitis. *Vet Q.* 2013;33:113-120.
164. Bayton WA, Wilson A, Fietin H, et al. Prednisolone therapy for chronic hepatitis in the English Springer Spaniel: a prospective study of 14 cases. In: *Proceeding of the 27th ECVIM Congress 2017*; September 14-16, 2017; Malta, Italy.
165. Kanemoto H, Sakai M, Sakamoto Y, et al. American Cocker Spaniel chronic hepatitis in Japan. *J Vet Intern Med.* 2013;27:1041-1048.
166. Ullal T, Ambrosini Y, Rao S, Twedt D, et al. The evaluation of cyclosporine in the treatment of chronic hepatitis in dogs. In: *Proceeding of the ACVIM 2018*; June 13-16, 2018; Seattle, WA.
167. Poitout F, Weiss DJ, Armstrong PJ. Cell-mediated immune responses to liver membrane protein in canine chronic hepatitis. *Vet Immunol Immunopathol.* 1997;57(3-4):169-178.
168. Shih JL, Keating JH, Freeman LM, Webster CRL. Chronic hepatitis in Labrador Retrievers: clinical presentation and prognostic factors. *J Vet Intern Med.* 2007;21:33-39.
169. Schultheiss PC, Bedwell CL, Hamar DW, Fettman MJ. Canine liver iron, copper, and zinc concentrations and association with histologic lesions. *J Vet Diagn Invest.* 2002;14:396-402.
170. Sevelius E. Diagnosis and prognosis of chronic hepatitis and cirrhosis in dogs. *J Small Anim Pract.* 1995;36:521-528.
171. Spee B, Mandigers PJ, Arends B, et al. Differential expression of copper-associated and oxidative stress related proteins in a new variant of copper toxicosis in Doberman Pinschers. *Comp Hepatol.* 2005;4:3-9.
172. Fietin H, Penning LC, Leegwater PA, et al. New canine models of copper toxicosis: diagnosis, treatment, and genetics. *Ann N Y Acad Sci.* 2014;1314:42-48.
173. Thornburg LP. Histomorphological and immunohistochemical studies of chronic active hepatitis in Doberman Pinschers. *Vet Pathol.* 1998;35:380-385.
174. Napier P. Hepatic necrosis with toxic copper levels in a two-year-old. *Can Vet J.* 1996;37:45.
175. Gómez Selgas A, Bexfield N, Scase TJ, Holmes MA, Watson P. Total serum bilirubin as a negative prognostic factor in idiopathic canine chronic hepatitis. *J Vet Diagn Invest.* 2014;26:246-251.
176. Raffan E, McCallum A, Scase TJ, Watson PJ. Ascites is a negative prognostic indicator in chronic hepatitis in dogs. *J Vet Intern Med.* 2009;23:63-66.
177. van den Ingh TS, Rothuizen J. Lobular dissecting hepatitis in juvenile and young adult dogs. *J Vet Intern Med.* 1994;8:217-220.
178. Jensen AL, Nielsen OL. Chronic hepatitis in three young standard poodles. *Zentralbl Veterinarmed A.* 1991;38:194-197.
179. Bennett AM, Davies JD, Gaskell CJ, Lucke VM. Lobular dissecting hepatitis in the dog. *Vet Pathol.* 1983;20:179-188.
180. Mizooku H, Kagawa Y, Matsuda K, et al. Histological and immunohistochemical evaluations of lobular dissecting hepatitis in American Cocker Spaniel dogs. *J Vet Med Sci.* 2013;75:597-603.
181. Bradley A, Aboellail T, Cotter A, et al. *Histologic Scoring and Clinical Outcomes of Hepatitis in 42 Standard Poodles.* Indianapolis, IN: ACVIM; 2015.
182. Hardy RM. Chronic hepatitis in Cocker Spaniels - another syndrome? In: *Proceedings 11th ACVIM Forum*; June 15-18, 1993; 256-258; Denver, CO.
183. Fry W, Lester C, Eteldal NM, Shaw S, DeLaforcade A, Webster CRL. Thromboelastography in dogs with chronic hepatopathies. *J Vet Intern Med.* 2017;31:419-426.
184. Doige CE, Furneaux RW. Liver disease and intrahepatic portal hypertension in the dog. *Can Vet J.* 1975;16:209-214.
185. Elhiblu MA, Dua K, Mohindroo J, Mahajan SK, Sood NK, Dhaliwal PS. Clinico-hemato-biochemical profile of dogs with liver cirrhosis. *Vet World.* 2015;8:487-491.
186. James FE, Knowles GW, Mansfield CS, Robertson ID. Ascites due to pre-sinusoidal portal hypertension in dogs: a retrospective analysis of 17 cases. *Aust Vet J.* 2008;86:180-186.
187. Im J, Burney DP, McDonough SP, et al. Canine hepatitis associated with intrahepatic bacteria in three dogs. *J Am Anim Hosp Assoc.* 2018;54:65-70.
188. Kilpatrick S, Dreistadt M, Frowde P, et al. Presence of systemic inflammatory response syndrome predicts a poor clinical outcome in dogs with a primary hepatitis. *PLoS One.* 2016;11:e0146560.
189. Toulza O, Center SA, Brooks MB, Erb HN, Warner KL, Deal W. Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. *J Am Vet Med Assoc.* 2006;229:1761-1771.
190. Strombeck DR, Gribble D. Chronic active hepatitis in the dog. *J Am Vet Med Assoc.* 1976;173:380-386.
191. Adam FH, German AJ, McConnell JF, et al. Clinical and clinicopathologic abnormalities in young dogs with acquired and congenital portosystemic shunts: 93 cases (2003-2008). *J Am Vet Med Assoc.* 2012;241:760-765.
192. Dirksen K, Verzijl T, Grinwis GC, et al. Use of serum microRNAs as biomarker for hepatobiliary diseases in dogs. *J Vet Intern Med.* 2016;30:1816-1823.
193. Dirksen K, Verzijl T, van den Ingh TS, et al. Hepatocyte-derived microRNAs as sensitive serum biomarkers of hepatocellular injury in Labrador Retrievers. *Vet J.* 2016;211:75-81.
194. Dirksen K, Burgener IA, Rothuizen J, et al. Sensitivity and specificity of plasma ALT, ALP, and bile acids for hepatitis in Labrador Retrievers. *J Vet Intern Med.* 2017;3:1017-1027.
195. Koenig EM, Fisher C, Bernard H, et al. The beagle dog microRNA tissue atlas: identifying translatable biomarkers of organ toxicity. *BMC Genomics.* 2016;17:649.
196. Oosthuyzen W, Ten Berg PWL, Francis B, et al. Sensitivity and specificity of microRNA-122 for liver disease in dogs. *J Vet Intern Med.* 2018;32:1637-1644.
197. Center SA. Serum bile acids in companion animal medicine. *Vet Clin North Am Small Anim Pract.* 1993;23:625-657.
198. Center SA, Baldwin BH, Erb HN, Tennant BC. Bile acid concentrations in the diagnosis of hepatobiliary disease in the dog. *J Am Vet Med Assoc.* 1985;187:935-940.

199. Center SA, ManWarren T, Slater MR, et al. Evaluation of twelve-hour preprandial and two-hour postprandial serum bile acids concentrations for diagnosis of hepatobiliary disease in dogs. *J Am Vet Med Assoc.* 1991;199:217-222.
200. Gerritzen-Bruning MJ, van den Ingh TS, et al. Diagnostic value of fasting plasma ammonia and bile acid concentrations in the identification of portosystemic shunting in dogs. *J Vet Intern Med.* 2006;20:13-19.
201. Goggs R, Serrano S, Szladovits B, Keir I, Ong R, Hughes D. Clinical investigation of a point-of-care blood ammonia analyzer. *Vet Clin Pathol.* 2008;37:198-206.
202. Sterczar A, Meyer HP, Boswijk HC, et al. Evaluation of ammonia measurements in dogs with two analyzers for use in veterinary practice. *Vet Rec.* 1999;144:523-526.
203. Odunayo A, Tobias KM, Okafor CC, Flatland B. Ammonia concentrations in canine whole blood, EDTA-anticoagulated whole blood, and plasma measured by use of a point-of-care ammonia meter. *Am J Vet Res.* 2017;78:1239-1244.
204. Rothuizen J, van den Ingh TS. Arterial and venous ammonia concentrations in the diagnosis of canine hepato-encephalopathy. *Res Vet Sci.* 1982;33:17-21.
205. Lidbury JA, Ivanek R, Suchodolski JS, Steiner JM. Putative precipitating factors for hepatic encephalopathy in dogs: 118 cases (1991-2014). *J Am Vet Med Assoc.* 2015;247:176-183.
206. Partington BP, Biller DS. Hepatic imaging with radiology and ultrasound. *Vet Clin North Am Small Anim Pract.* 1995;25:453-480.
207. Gaschen L. Update on hepatobiliary imaging. *Vet Clin Small Anim.* 2009;39:439-467.
208. D'Anjou MA, Penninck DG. Liver. In: Penninck D, d'Anjou MA, eds. *Atlas of Small Animal Ultrasonography.* Ames, IA: John Wiley & Sons; 2015:183-238.
209. Larson MM. Ultrasound imaging of the hepatobiliary system and pancreas. *Vet Clin North Am Small Anim Pract.* 2016;46:453-480.
210. Lidbury JA. Getting the most out of liver biopsy. *Vet Clin North Am Small Anim Pract.* 2017;47:569-583.
211. Kemp SD, Panciera DL, Larson MM, Saunders GK, Werre SR. A comparison of hepatic sonographic features and histopathologic diagnosis in canine liver disease: 138 cases. *J Vet Intern Med.* 2013;27:806-813.
212. Feeney DA, Anderson KL, Ziegler LE, Jessen CR, Daubs BM, Hardy RM. Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. *Am J Vet Res.* 2008;69:212-221.
213. Warren-Smith CM, Andrew S, Mantis P, Lamb CR. Lack of associations between ultrasonographic appearance of parenchymal lesions of the canine liver and histological diagnosis. *J Small Anim Pract.* 2012;53:168-173.
214. Caldwell SH, Tripodi A, Primignani M, et al. Changing concepts of cirrhotic coagulopathy. *Am J Gastroenterol.* 2017;112:274-281.
215. Szatmari V, Rothuizen J, van den Ingh TS, et al. Ultrasonographic findings in dogs with hyperammonemia: 90 cases (2000-2002). *J Am Vet Med Assoc.* 2004;224:717-727.
216. Szatmari V, Rothuizen J. Ultrasonographic identification and characterization of congenital portosystemic shunts and portal hypertensive disorders in dogs and cats. In: Rothuizen J, Bunch SE, Charles JA, et al., eds. *Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases.* WSAVA Liver Standardization Group. Philadelphia, PA: Saunders Elsevier; 2006:15-39.
217. Lamb CR, Mahoney PN. Comparison of three methods for calculating portal blood flow velocity in dogs using duplex Doppler ultrasonography. *Vet Radiol Ultrasound.* 1994;35:190-194.
218. Lamb CR, Wrigley RH, Simpson KW, et al. Ultrasonographic diagnosis of portal vein thrombosis in four dogs. *Vet Radiol Ultrasound.* 1996;37:121-129.
219. Bertolini G. Acquired portal collateral circulation in the dog and cat. *Vet Radiol Ultrasound.* 2010;51:25-33.
220. Laurensen MP, Hopper K, Herrera MA, Johnson EG. Concurrent diseases and conditions in dogs with splenic vein thrombosis. *J Vet Intern Med.* 2010;24:1298-1304.
221. Respass M, O'Toole TE, Taeymans O, Rogers CL, Johnston A, Webster CRL. Portal vein thrombosis in 33 dogs: 1998-2011. *J Vet Intern Med.* 2012;26:230-237.
222. French JM, Twedt DC, Rao A, et al. Comparison of computed tomographic angiography and ultrasonography in the diagnosis of acute canine pancreatitis. In: *Proceeding of ECVIM 2018, Rotterdam, The Netherlands*; 2018.
223. Chundru S, Kalb B, Arif-Tiwari H, Sharma P, Costello J, Martin DR. MRI of diffuse liver disease: characteristics of acute and chronic diseases. *Diagn Interv Radiol.* 2014;20:200-208.
224. Bigge LA, Brown DJ, Penninck DG. Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996). *J Am Anim Hosp Assoc.* 2001;37:228-233.
225. McDevitt HL, Mayhew PD, Giuffrida MA, et al. Short-term clinical outcome of laparoscopic liver biopsy in dogs: 106 cases (2003-2013). *J Am Vet Med Assoc.* 2016;248:83-90.
226. Petre SL, McClaran JK, Bergman PJ, et al. Safety and efficacy of laparoscopic hepatic biopsy in dogs: 80 cases (2004-2009). *J Am Vet Med Assoc.* 2012;240:181-185.
227. Barr F. Percutaneous biopsy of abdominal organs under ultrasound guidance. *J Small Anim Pract.* 1995;36:105-113.
228. Hitt ME, Hanna P, Singh A. Percutaneous transabdominal hepatic needle biopsies in dogs. *Am J Vet Res.* 1992;53:785-787.
229. Pavlick M, Webster CRL, Penninck DP. Bleeding risk assessment for percutaneous ultrasound guided hepatic biopsy in dogs and cats. *ACVIM 2017; June 8-10, 2017; National Harbor, MD.*
230. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. *J Vet Emerg Crit Care.* 2011;21:589-604.
231. Prins M, Schellens CJ, van Leeuwen MW. Coagulation disorders in dogs with hepatic disease. *Vet J.* 2010;185:163-168.
232. Webster CR. Hemostatic disorders associated with hepatobiliary disease. *Vet Clin North Am Small Anim Pract.* 2017;47:601-615.
233. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. *Blood.* 2010;116:878-885.
234. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. *Am J Clin Pathol.* 1990;94:747-753.
235. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. *Dig Dis Sci.* 1981;26:388-393.
236. Shah A, Amarapurkar D, Dharod M, et al. Coagulopathy in cirrhosis: a prospective study to correlate conventional tests of coagulation and bleeding following invasive procedures in cirrhotics. *Indian J Gastroenterol.* 2015;34:359-364.
237. DeAngelis GA, Khot R, Haskal ZJ, et al. Bleeding risk and management in interventional procedures in chronic liver disease. *J Vasc Interv Radiol.* 2016;27:1665-1674.
238. Grant A, Neuberger J. Guidelines for the use of liver biopsy in clinical practice. *British Society of Gastroenterology. Gut.* 1999;45(Suppl IV):IVI-IVII.
239. Patel IJ, Davidson JC, Nikolic B, et al. Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. *J Vasc Interv Radiol.* 2012;23:727-736.
240. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. *Hepatology.* 2009;49:1017-1044.

241. Daure E, Ross L, Webster CR. Gastroduodenal ulceration in small animals: part 1. Pathophysiology and epidemiology. *J Am Anim Hosp Assoc.* 2017;53:1-10.
242. Daure E, Ross L, Webster CR. Gastroduodenal ulceration in small animals: part 2. Proton pump inhibitors and Histamine-2 receptor antagonists. *J Am Anim Hosp Assoc.* 2017;53:11-23.
243. Willis SE, Jackson ML, Meric SM, Rousseaux CG. Whole blood platelet aggregation in dogs with liver disease. *Am J Vet Res.* 1989;50:1893-1897.
244. Wennogle SA, Olver C, Twedt D. Coagulation abnormalities and their correlation to use of Gelfoam to aid in hemostasis during laparoscopic liver biopsy in dogs. In: *Proceeding of ACVIM 2017*; June 8-10, 2017; National Harbor, MD.
245. Peterson TJ, Webb AM, Vipler BS. Use of thromboelastography in the management of liver cirrhosis and accelerated intravascular coagulation and fibrinolysis (AICF). *BMJ Case Rep.* 2016;2016:pii: bcr2016218294.
246. De Pietri L, Bianchini M, Montalti R, et al. Thromboelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial. *Hepatology.* 2016;63:566-573.
247. Pandey CK, Saluja V, Gaurav K, Tandon M, Pandey VK, Bhadoria AS. K time & maximum amplitude of thromboelastogram predict post-central venous cannulation bleeding in patients with cirrhosis: a pilot study. *Indian J Med Res.* 2017;145:84-89.
248. Kelley D, Lester C, DeLaforcade A, Webster CRL. Thromboelastographic evaluation of dogs with congenital portosystemic shunts. *J Vet Intern Med.* 2013;27:1262-1267.
249. Kelley D, Lester C, Shaw S, de Laforcade A, Webster CRL. Thromboelastographic evaluation of dogs with acute liver disease. *J Vet Intern Med.* 2015;29:1053-1062.
250. Giannini EG, Giambruno E, Brunacci M, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients. *Ann Hepatol.* 2018;17:830-835.
251. Thakrar SV, Mallett SV. Thrombocytopenia in cirrhosis: impact of fibrinogen on bleeding risk. *World J Hepatol.* 2017;9:318-325.
252. Wanty C, Helleputte T, Smets F, Sokal EM, Stephenne X. Assessment of risk of bleeding from esophageal varices during management of biliary atresia in children. *J Pediatr Gastroenterol Nutr.* 2013;56:537-543.
253. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. *Science.* 1980;207:541-543.
254. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. *Transfusion.* 2001;41:977-983.
255. Rothuizen J, Twedt DC. Liver biopsy techniques. *Vet Clin Small Anim.* 2009;39:469-480.
256. Sharkey LC, Dial SM, Matz ME. Maximizing the diagnostic value of cytology in small animal practice. *Vet Clin North Am Small Anim Pract.* 2007;37:351-372.
257. Wang KY, Panciera DL, Al-Rukibat RK, et al. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). *J Am Vet Med Assoc.* 2004;224:75-78.
258. Roth L. Comparison of liver cytology and biopsy diagnoses in dogs and cats: 56 cases. *Vet Clin Pathol.* 2001;30:35-38.
259. Bahr KL, Sharkey LC, Murakami T, et al. Accuracy of US-guided FNA of focal liver lesions in dogs: 140 cases (2005-2008). *J Am Anim Hosp Assoc.* 2013;49:190-196.
260. Petrelli M, Scheuer PA. Variation in subcapsular liver structure and its significance in the interpretation of wedge biopsies. *J Clin Pathol.* 1967;20:743-748.
261. Vasanjee SC, Bubenik LJ, Hosgood G, et al. Evaluation of hemorrhage, sample size, and collateral damage for five hepatic biopsy methods in dogs. *Vet Surg.* 2006;35:86-93.
262. Center SA, McDonough SP, Bogdanovic L. Digital image analysis of rhodanine-stained liver biopsy specimens for calculation of hepatic copper concentrations in dogs. *Am J Vet Res.* 2013;74:1474-1480.
263. Johnston AN, Center SA, McDonough SP, et al. Influence of biopsy specimen size, tissue fixation, and assay variation on copper, iron, and zinc concentrations in canine livers. *Am J Vet Res.* 2009;70:1502-1511.
264. Faa G, Nurchi V, Demelia L, et al. Uneven hepatic copper distribution in Wilson's disease. *J Hepatol.* 1995;22:303-308.
265. Bravo AA, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med.* 2001;344:495-500.
266. Kemp SD, Zimmerman KL, Panciera DL, et al. A comparison of liver sampling techniques in dogs. *J Vet Intern Med.* 2015;29:51-57.
267. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. *J Am Vet Med Assoc.* 2002;220:1483-1490.
268. Kemp SD, Zimmerman KL, Panciera DL, et al. Histopathologic variation between liver lobes in dogs. *J Vet Intern Med.* 2015;29:58-62.
269. Lidbury JA, Rodrigues Hoffmann A, et al. Interobserver agreement using histological scoring of the canine liver. *J Vet Intern Med.* 2017;31:778-783.
270. Sepesy LM, Center SA, Randolph JF, et al. Vacuolar hepatopathy in dogs: 336 cases (1993-2005). *J Am Vet Med Assoc.* 2006;229:246-252.
271. Desmet VJ. Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered. *Virchows Arch.* 2011;458:251-259.
272. Yoshioka K, Enaga S, Taniguchi K, et al. Morphological characterization of ductular reactions in canine liver disease. *J Comp Pathol.* 2004;130:92-98.
273. Braselton WE, Stuart KJ, Mullaney TP, Herdt TH. Biopsy mineral analysis by inductively coupled plasma-atomic emission spectroscopy with ultrasonic nebulization. *J Vet Diag Invest.* 1997;9:394-340.
274. Bode P. Instrumental neutron activation analysis in a routine way. *J Trace Microprobe Tech.* 1990;8:139.
275. Teske E, Brinkhuis BGAM, Bode P, et al. Cytological detection of copper for the diagnosis of inherited copper toxicosis in Bedlington Terriers. *Vet Rec.* 1992;131:30-32.
276. Robert M, Sofair AN, Thomas A, et al. A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. *Clin Gastroenterol Hepatol.* 2009;7:335-338.
277. Rousselet MC, Michalak S, Dupré F, et al. Sources of variability in histological scoring of chronic viral hepatitis. *Hepatology.* 2005;41:257-264.
278. Greene G. *Infectious Disease of the Dog and Cat*. 4th ed. St Louis, MO: Elsevier Saunders; 2012.
279. Kearns S. Infectious hepatopathies in dogs and cats. *Top Companion Anim Med.* 2009;24:189-198.
280. Sykes JE, Hartmann K, Lunn KF, et al. ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. *J Vet Intern Med.* 2011;25:1-13.
281. Schuller S, Francey T, Hartmann K, et al. European consensus statement on leptospirosis in dogs and cats. *J Small Anim Pract.* 2015;56:159-179.
282. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol.* 2014;109:950-966.
283. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. *Aliment Pharmacol Ther.* 2013;37:1132-1156.
284. Seboe M, Schulz L, Lohse AW. "Autoimmune(-like)" drug and herb induced liver injury: new insights into molecular pathogenesis. *Int J Mol Sci.* 2017;18:E1954. <https://doi.org/10.3390/ijms18091954>.

285. Yamashita YI, Imai K, Mima K, et al. Idiosyncratic drug-induced liver injury: a short review. *Hepatol Commun*. 2017;1:494-500.
286. Gaetke LM, Chow-Johnson HS. Copper: toxicological relevance and mechanisms. *Arch Toxicol*. 2014;88:1929-1932.
287. Bergstrom RF, Kay DR, Wagner JG. The pharmacokinetics of penicillamine in a female mongrel dog. *J Pharmacokinet Biopharm*. 1981;9:603-621.
288. Schumacher K. Basis of immunosuppressive effect of D-penicillamine. *Internist*. 1975;16:450-460.
289. Kazemi K, Geramizadeh B, Nikeghbalan S, et al. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease. *Exp Clin Transplant*. 2008;6:261-263.
290. Epstein O, De Villiers D, Jain S, et al. Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. *N Engl J Med*. 1979;300:274-278.
291. DeVore DP, Gruebel RJ, Hutson TB, et al. Effects of D-penicillamine on lymphocyte modulation of synovial collagenase production. *Agents Actions*. 1979;9:172-176.
292. Kato N, Nakamura M, Uchiyama T. ¹H NMR studies of the reactions of copper(I) and copper(II) with D-penicillamine and glutathione. *J Inorg Biochem*. 1999;75:117-121.
293. Langlois DK, Lehner AF, Buchweitz JP, et al. Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs. *J Vet Intern Med*. 2013;27:1071-1076.
294. Allen KG, Twedt DC, Hunsaker HA. Tetramine cupruric agents: a comparison in dogs. *Am J Vet Res*. 1987;48:28-30.
295. Twedt DC, Hunsaker HA, Allen KG. Use of 2,3,2-tetramine as a hepatic copper chelating agent for treatment of copper hepatotoxicosis in Bedlington Terriers. *J Am Vet Med Assoc*. 1988;192:52-56.
296. Weiss KH, Cżlonkowska A, Hedera P, Ferenci P. WTX101—an investigational drug for the treatment of Wilson disease. *Expert Opin Investig Drugs*. 2018;27:561-567.
297. Chan CM, Langlois DK, Buchweitz JP, et al. Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration to healthy dogs. *Am J Vet Res*. 2015;76:445-453.
298. Cżlonkowska A, Litwin T. Wilson disease – currently used anticopper therapy. *Handb Clin Neurol*. 2017;142:181-191.
299. Brewer GJ, Dick RD, Schall W, et al. Use of zinc acetate to treat copper toxicosis in dogs. *J Am Vet Med Assoc*. 1992;201:564-568.
300. Sokol RJ, Devereaux M, Khandwala RA. Effect of dietary lipid and vitamin E on mitochondrial lipid peroxidation and hepatic injury in the bile duct-ligated rat. *J Lipid Res*. 1991;32:1349-1357.
301. von Herbay A, de Groot H, Hegi U, et al. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. *J Hepatol*. 1994;20:41-46.
302. Sinha S, Christopher R, Arunodaya GR, et al. Is low serum tocopherol in Wilson's disease a significant symptom? *J Neurol Sci*. 2005;228:121-123.
303. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. *Am J Vet Res*. 2002;63:1187-1197.
304. Heidarpour M, Soltani S, Mohri M, et al. Canine visceral leishmaniasis: relationships between oxidative stress, liver and kidney variables, trace elements, and clinical status. *Parasitol Res*. 2012;111:1491-1496.
305. Souza CC, Barreto Tde O, da Silva SM, et al. A potential link among antioxidant enzymes, histopathology and trace elements in canine visceral leishmaniasis. *Int J Exp Pathol*. 2014;95:260-270.
306. Vince AR, Hayes MA, Jefferson BJ, et al. Hepatic injury correlates with apoptosis, regeneration, and nitric oxide synthase expression in canine chronic liver disease. *Vet Pathol*. 2014;51:932-945.
307. Beckman JK, Borowitz SM, Greene HL, et al. Promotion of iron-induced rat liver microsomal lipid peroxidation by copper. *Lipids*. 1988;23:559-563.
308. Häussinger D, Kordes C. Mechanisms of tauroursodeoxycholate-mediated hepatoprotection. *Dig Dis*. 2017;35:224-231.
309. Beuers U, Trauner M, Jansen P, et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. *J Hepatol*. 2015;62:S25-S37.
310. Reardon J, Hussaini T, Alsaif M, et al. Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: a systematic review. *J Clin Transl Hepatol*. 2016;28(4):192-205.
311. Meyer DJ, Thompson MB, Senior D. Use of ursodeoxycholic acids in a dog with chronic hepatitis: effects on serum hepatic tests and endogenous bile acid composition. *J Vet Intern Med*. 1997;11(3):195-197.
312. Webster CR, Cooper J. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. *Vet Clin North Am Small Anim Pract*. 2009;39(3):631-652.
313. Ramani K, Lu SC. Methionine adenosyltransferases in liver health and diseases. *Liver Res*. 2017;1:103-111.
314. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. *Physiol Rev*. 2012;92:1515-1542.
315. Center SA, Warner KL, McCabe J, et al. Evaluation of the influence of s-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs. *Am J Vet Res*. 2005;66:330-341.
316. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. *Am J Med*. 1987;83:35-42.
317. Griffin DW, Whalen MO, Filburn CR. Bioavailability of a novel formulation of S-adenosylmethionine in beagle dogs. In: Proceeding of the ACVIM Forum 2009; June 3-6, 2009; Montreal, QC, Canada.
318. Sturgess CP. Measurement of the S-adenosyl methionine (SAME) content in a range of commercial veterinary SAME supplements. *J Small Anim Pract*. 2014;55:447-450.
319. Anstee QM, Day CP. S-adenosylmethionine (SAME) therapy in liver disease: a review of current evidence and clinical utility. *J Hepatol*. 2012;57:1097-1109.
320. Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. *PLoS One*. 2015;16(10):e0121224.
321. Wallace KP, Center SA, Hickford FH, et al. S-adenosyl-L-methionine (SAME) for the treatment of acetaminophen toxicity in a dog. *J Am Anim Hosp Assoc*. 2002;38:246-254.
322. Polyak SJ, Ferenci P, Pawlowsky JM. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. *Hepatology*. 2013;57:1262-1271.
323. Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. *J Am Med Assoc*. 2012;308:274-282.
324. Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol*. 2017;15:1940-1949.
325. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. *J Vet Pharmacol Ther*. 2007;30:132-138.
326. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Silyphos). *Altern Med Rev*. 2005;10:193-203.
327. Abenavoli L, Izzo AA, Milić N, et al. Milk thistle (*Silybum marianum*): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. *Phytother Res*. 2018;32:2202-2213.
328. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. *Eur J Drug Metab Pharmacokinet*. 1990;15:333-338.
329. Galli F, Azzi A, Birringer M, et al. Vitamin E: emerging aspects and new directions. *Free Radic Biol Med*. 2017;102:16-36.
330. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for

- the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology*. 2012;142:1592-1609.
331. Banini BA, Sanyal AJ. Treatment of NASH: what helps beyond weight loss? *Am J Gastroenterol*. 2017;112:821-824.
 332. Fryer MJ. Potential of vitamin E as an antioxidant adjunct in Wilson's disease. *Med Hypotheses*. 2009;73:1029-1030.
 333. Twedt DC, Webb CB, Tetrick MA. The effect of dietary vitamin E on the clinical laboratory and oxidant status of dogs with chronic hepatitis. *J Vet Intern Med*. 2003;17:418A.
 334. Sakai M, Tateishi H, Koide M, et al. Azathioprine and prednisolone treatment in Labrador Retrievers with chronic hepatitis. In: 2014 Proceeding of the ACVIM Forum; June 4-7, 2014; Nashville, TN.
 335. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol*. 2019;70(1):172-193.
 336. Yao CK, Fung J, Chu NHS, Tan VPY. Dietary interventions in liver cirrhosis. *J Clin Gastroenterol*. 2018;52:663-673.
 337. Haberl J, Zollner G, Fickert P, et al. To salt or not to salt? That is the question in cirrhosis. *Liver Int*. 2018;38:1148-1159.
 338. Bernardi M, Zaccherini G. Approach and management of dysnatremias in cirrhosis. *Hepatol Int*. 2018;12:487-499.
 339. Hoffman AR, Gold RM, Sucholdolski JS, et al. Hepatic fibrosis is associated with shortened survival times in dogs with chronic hepatitis. ACVIM 2017; June 8-10, 2017; National Harbor, MD.
 340. Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. *J Vet Intern Med*. 2011;25:169-186.
 341. Rothuizen J. Important clinical syndromes associated with liver disease. *Vet Clin North Am Small Anim Pract*. 2009;39:419-437.
 342. Eulenberg VM, Lidbury JA. Hepatic fibrosis in dogs. *J Vet Intern Med*. 2018;32:26-41.
 343. Gow AG. Hepatic encephalopathy. *Vet Clin North Am Small Anim Pract*. 2017;47:585-599.
 344. Lidbury JA, Cook AK, Steiner JM. Hepatic encephalopathy in dogs and cats. *J Vet Emerg Crit Care (San Antonio)*. 2016;26:471-487.
 345. Tivers MS, Handel I, Gow AG, et al. Attenuation of congenital portosystemic shunt reduces inflammation in dogs. *PLoS One*. 2015;10(2):e0117557.
 346. Kaneko Y, Torisu S, Hagio M, et al. A case report of suspected hepatopulmonary syndrome secondary to ductal plate malformation with chronic active hepatitis in a dog. *J Vet Med Sci*. 2016;78:493-497.
 347. Kaneko Y, Torisu S, Kobayashi T, et al. Arterial blood gas anomaly in canine hepatobiliary disease. *J Vet Med Sci*. 2016;77:1633-1638.
 348. Yan G, He J, Yu Y, et al. Mechanical characteristics of the pulmonary artery in beagle dogs with hepatopulmonary syndrome and portopulmonary hypertension. *Biomed Rep*. 2016;4:51-54.
 349. Sakamoto Y, Sakai M, Watari T. Portal vein/aorta ratio in dogs with acquired portosystemic collaterals. *J Vet Intern Med*. 2017;31:1382-1387.
 350. Sakamoto Y, Sakai M, Watari T. Hepatic and plasma endothelin-1 in dogs with chronic hepatitis. *J Vet Intern Med*. 2017;31:764-769.
 351. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol*. 2015;63:743-752.
 352. La Mura V, Nicolini A, Tosetti G, et al. Cirrhosis and portal hypertension: the importance of risk stratification, the role of hepatic venous pressure gradient measurement. *World J Hepatol*. 2015;7:688-695.
 353. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology*. 2009;49:2087-2107.
 354. Marks SL, Kook PH, Papich MG, et al. ACVIM consensus statement: support for rational administration of gastrointestinal protectants to dogs and cats. *J Vet Intern Med*. 2018;32:1823-1840.
 355. Mazaki-Tovi M, Segev G, Yas-Natan E, et al. Serum gastrin concentrations in dogs with liver disorders. *Vet Rec*. 2012;171:19.
 356. Wagner KA, Hartmann FA, Trepanier LA. Bacterial culture results from liver, gallbladder, or bile in 248 dogs and cats evaluated for hepatobiliary disease: 1998-2003. *J Vet Intern Med*. 2007;21:417-424.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Webster CRL, Center SA, Cullen JM, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. *J Vet Intern Med*. 2019; 33:1173-1200. <https://doi.org/10.1111/jvim.15467>